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CHAPTER 1. Background: Diverse Functions of HBEGF During Pregnancy 
1. Introduction 
Each month, the uterus prepares to receive a viable blastocyst under the 
direction of estrogen (E2) and progesterone (P4).  The sex steroid hormones induce 
many changes in the endometrium that enhance its receptivity to an implanting 
blastocyst (Dey et al., 2004).  Among these changes is the expression of secreted and 
membrane-bound signaling factors that influence embryo adhesion necessary for 
attachment to the luminal lining and later for invasion into the decidualized stroma.  The 
embryo is also a source of several important factors, some of which are produced to 
augment the preparation of the endometrium.  The concurrent developmental programs 
of the embryo and endometrium influence each other to synchronize their progression 
and produce an optimal environment for implantation.  One critical factor that appears 
around the time of implantation is heparin-binding epidermal growth factor (EGF)-like 
growth factor (HBEGF).  Evidence supporting a central role for HBEGF during 
implantation in mice is abundant and was recently reviewed (Lim and Dey, 2009). The 
cellular processes and regulatory factors that mediate the developmental program 
during blastocyst implantation have also been reviewed previously (Armant, 2005; 
Armant et al., 2000).  The focus of this article is on the many timely influences of 
HBEGF and the EGF signaling system upon trophoblast cells in the peri- and post-
implantation environment as pregnancy is established. 
HBEGF and other members of the EGF family are synthesized as 
transmembrane proteins (e.g., proHBEGF) that can signal to their receptors on adjacent 
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cells (juxtacrine) or become secreted through the shedding activity of 
metalloproteinases that cleave the extracellular domain (Riese and Stern, 1998). The 
secreted form (e.g., sHBEGF) is free to bind receptors on the same cell (autocrine) or 
distant cells (paracrine). Processing of proHBEGF to sHBEGF and subsequent 
signaling through its receptors is illustrated in Fig. 1.1 EGF family growth factors, 
operating through four HER/erbB receptor tyrosine kinases, induce receptor 
dimerization and autophosphorylation, leading to downstream signaling that involves an 
extensive array of pathways (Holbro and Hynes, 2004a).  HBEGF requires heparan 
sulfate proteoglycan (HSPG) as a cofactor for binding to its receptors, HER1 (a.k.a. 
EGF receptor) and HER4.  Although HBEGF does not bind directly to HER2 or HER3, 
they can participate in downstream signaling through heterodimerization with other 
ligated HER proteins. 
HBEGF performs a variety of functions in different cell systems (Raab and 
Klagsbrun, 1997).  In its transmembrane form, proHBEGF appears to bind HER1 or 
HER4 of adjacent cells, participating in cell attachment or eliciting further signaling 
(Higashiyama et al., 1995; Raab et al., 1996).  HBEGF induces chemotaxis and mitosis 
of NIH 3T3 cells through HER1 signaling (Elenius et al., 1997). Using a variety of 
carcinoma cell lines, it was shown that p53 expression induced by DNA damage 
subsequently upregulates HBEGF protein, which utilizes both MEK/ERK and PI3K/Akt 
pathways to inhibit cellular apoptosis (Fang et al., 2001).  It also inhibits apoptosis in 
ovarian cancer, breast cancer, gastric cancer, melanoma and glioblastoma cells by 
activating HER1 and downstream ERK (Yotsumoto et al., 2008).  Many of the diverse  
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cellular activities regulated by HBEGF transpire in the course of embryonic development 
as the placental tissues emerge. 
1.1. Early Cyclical Regulation of HBEGF in the Endometrium 
Rodents 
It was first determined that HBEGF plays a central role in the establishment of 
pregnancy in experiments conducted using mice and rats.  HBEGF expression is 
regulated in the mouse endometrium by leukemia inhibitory factor (LIF) (Song et al., 
2000), a cytokine required for implantation (Stewart et al., 1992), as well as by P4 and 
E2 (Wang et al., 1994).  LIF is necessary for the expression of HBEGF, amphiregulin 
(AREG), and epiregulin (EREG) mRNA in the luminal epithelium of the mouse uterus 
surrounding a newly implanted blastocyst, as evaluated in LIF-/- mice (Song et al., 
2000).  In both mice and rats, E2 upregulates HBEGF mRNA and protein levels in the 
luminal epithelium, whereas P4 and E2 together upregulate its expression in the stroma 
(Wang et al., 1994; Zhang et al., 1994a; Zhang et al., 1994b).  This indicates that 
HBEGF mRNA is transcribed in vivo under conditions that normally stimulate cellular 
proliferation in the endometrium (Zhang et al., 1994b).  It is important to note, however, 
that this hormonal regulation of HBEGF in the non-pregnant uterus does not necessarily 
trigger its expression during pregnancy, but may prepare the endometrium to respond to 
additional signals that induce HBEGF expression in specific cell populations. 
The regulation of HBEGF in stromal cells suggests that it has a unique role in 
preparing the uterus for decidualization, in which stromal cells accumulate lipid and 
glycogen vacuoles and increase their secretion of a fibrous matrix.  Near the implanting 
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blastocyst, there is an increase in vascular permeability and the expression of genes 
such as Bmp-2, Fgf-2, and Wnt-4 (Abrahamsohn and Zorn, 1993; Farrar and Carson, 
1992; Paria et al., 2001).  Beads coated with HBEGF can induce local increases in 
vascular permeability and upregulate expression of Bmp-2, suggesting that HBEGF 
participates in preparing the uterus to receive an implanting blastocyst (Paria et al., 
2001).  In cultured mouse stromal cells, HBEGF induces decidualization-like changes, 
including the upregulation of Cyclin D3 and the induction of stromal cell polyploidy (Tan 
et al., 2004).   
Humans & Non-human Primates 
HBEGF appears to regulate the endometrial cycle in other mammals, including 
humans and non-human primates.  In contrast to rodents, in which sex steroids prepare 
the uterus for eventual HBEGF expression, E2 and P4 stimulate HBEGF expression in 
human endometrium prior to the appearance of a blastocyst (Lessey et al., 2002a), and, 
in baboons, it is under the control of P4 (Leach et al., 2001).  As a result of its regulation 
by steroids, HBEGF accumulates in a cyclical fashion. During the late proliferative 
phase until the early secretory phase of the menstrual cycle in humans, HBEGF is 
predominantly localized in the stromal compartment of the endometrium (Chobotova et 
al., 2002a; Leach et al., 1999b; Yoo et al., 1997a).  Although transcript levels are 
present in the luminal and glandular epithelia, protein levels do not appreciably 
accumulate at this time (Leach et al., 1999b; Yoo et al., 1997a).  These findings are 
consistent with evidence from baboons where protein and message levels rise in the 
stroma during the proliferative phase and decline by day 5 post-ovulation (Leach et al., 
2001).  The correlation of HBEGF with E2 levels is strengthened by ex vivo evidence 
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demonstrating that HBEGF transcription is induced by E2 in stromal cells.  Proliferative 
phase human stromal cells, when treated with either E2 or P4, upregulate transcription 
of HBEGF, though if treated with both steroids together, expression will appear in both 
stroma and the luminal epithelial cells (Lessey et al., 2002a).  When interpreted in light 
of the menstrual cycle, this data suggests that the high E2 levels prior to ovulation 
induce HBEGF expression in stromal cells.   
In the early secretory phase, HBEGF expression is induced in the luminal 
epithelium by the combination of E2 and P4 present at that time.  Consistent with this 
idea, HBEGF expression decreases in the stromal compartment during the early 
secretory phase, coincident with decreasing E2 levels, but increases in both luminal and 
glandular epithelial cells (Leach et al., 1999b; Yoo et al., 1997a).  HBEGF mRNA levels 
peak in the luminal and glandular epithelia during the mid secretory phase, just prior to 
the “window of implantation” (Yoo et al., 1997a).  Protein levels follow shortly thereafter, 
rising in the early secretory phase and peaking during the window of implantation (days 
19-22) when the uterus is optimally receptive to a blastocyst (Leach et al., 1999b).  
Baboons display a similar pattern in which HBEGF protein levels are highest 5 to 10 
days post-ovulation (Leach et al., 2001).  In rhesus monkeys, HBEGF increases during 
the proliferative phase, peaks during the window of implantation, and declines thereafter 
(Yue et al., 2000).  Its maximal expression during the mid secretory phase supports the 
view that HBEGF is a key regulator of blastocyst implantation.  Indeed, HBEGF is 
localized on the apical surface of human luminal epithelial cells and on the surface of 
pinopodes when it is at maximal levels in the human endometrium (Stavreus-Evers et 
al., 2002; Yoo et al., 1997a). 
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The decidualization reaction in humans is completely under the control of the sex 
steroids (Kodaman and Taylor, 2004), as opposed to rodents that have an estrous cycle 
that depends upon cues from the embryo (Dey et al., 2004). The human menstrual 
cycle prepares the uterus for implantation prior to arrival of an embryo, beginning in the 
early secretory phase, and reaching prominence by the window of implantation.  In 
humans, several stimuli that induce stromal cell decidualization appear to do so through 
upregulation of HBEGF.  If stromal cells are treated with 8-Br-cAMP, which is known to 
artificially induce decidualization, the soluble form of HBEGF is upregulated, as are its 
receptors, HER1 and HER4 (Chobotova et al., 2005).  HBEGF then induces stromal cell 
production of prolactin and insulin-like growth factor binding protein-1, which naturally 
induce decidualization (Chobotova et al., 2005).  Important for decidualization, HBEGF 
stimulates stromal cell growth via HER1, though not through HER4 (Chobotova et al., 
2002a).  The proliferative activity of HBEGF could be the result of its upregulation of IL-
11 secretion (Karpovich et al., 2003).  When stromal cells are treated with transforming 
growth factor-β (TGFB) or tumor necrosis factor-α (TNFA), HBEGF expression is 
induced, which subsequently protects against apoptosis (Chobotova et al., 2005).  Both 
the transmembrane and soluble forms of HBEGF are induced by these treatments, 
suggesting that HBEGF could be acting in an autocrine, paracrine or juxtacrine fashion 
as a survival factor (Chobotova et al., 2005).  In addition, TNFA synergizes with HBEGF 
to stimulate cell growth by upregulating EGFR expression in stromal cell membranes 
(Chobotova et al., 2002a).  More work is needed to determine which pathways are 
involved downstream of HBEGF signaling in stromal cells. 
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Decidualization and cytoprotection are only two of the important roles for HBEGF 
in the endometrium.  HBEGF or conditioned medium from E2- and P4-treated stromal 
cells upregulates ITGB3, LIF and homeobox A10 (HOXA10) mRNA in primary human 
luminal epithelial cells (Liu et al., 2007) and β3 integrin mRNA in Ishikawa cells (Lessey 
et al., 2002a).  Each of the corresponding proteins contributes to a uterine luminal 
epithelial surface that is receptive to an implanting blastocyst.  ITGAV/ITGB3 serves as 
an attachment factor for osteopontin (secreted phosphoprotein 1, SPP1).  SPP1 and 
ITGAV/ITGB3 are localized to both the glandular and luminal epithelia during the mid to 
late secretory phase, presumably to mediate embryo attachment (Apparao et al., 2001; 
Brown et al., 1992; Carson et al., 2002; Kao et al., 2002; Nardo et al., 2002; von Wolff et 
al., 2001).  LIF stimulates human embryo development to the blastocyst stage (Sargent 
et al., 1998).  In mice, LIF expression in the uterus is essential for embryo implantation 
(Stewart et al., 1992), as is uterine expression of HOXA10 (Satokata et al., 1995).  
HOXA10 message and protein are both found in the human endometrium most 
abundantly during the mid-secretory phase (Cermik et al., 2001; Gui et al., 1999; Li et 
al., 2002; Taylor et al., 1998).  It has been suggested that HOXA10 induction by P4 
during the window of implantation leads to a block in the stromal cell cycle, facilitating 
decidualization (Qian et al., 2005).  Thus, the stimulatory effects of HBEGF upon 
stromal cells appear to be important not only in decidualization, but also in the 
preparation of the uterine luminal epithelium for an attaching blastocyst. 
1.2. The Role of HBEGF at Implantation 
Rodents 
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Expression of HBEGF in the pregnant mouse uterus is necessary for the timely 
and successful implantation of a blastocyst (Xie et al., 2007).  Evidence suggests that 
HBEGF expression during pregnancy is not induced by sex steroid, as in the non-
pregnant uterus (Wang et al., 1994), but by the presence of a blastocyst (Das et al., 
1994c).  HBEGF mRNA is expressed in the uterine epithelium exclusively at the site of 
implantation 6-7 hr before attachment occurs, followed by an accumulation of the 
protein during attachment (Das et al., 1994c).  Physiological interactions between the 
endometrium and blastocyst can be examined by experimentally-induced delayed 
implantation in ovariectomized mice treated with P4 (Yoshinaga and Adams, 1966).  
HBEGF expression does not occur during delayed implantation until the blastocyst is 
activated by administration of E2 (Das et al., 1994c), suggesting that the blastocyst 
induces HBEGF expression in the uterine luminal epithelium.  Evidence from the 
hamster shows that HBEGF mRNA is expressed throughout the apical surface of the 
luminal epithelium prior to blastocyst hatching and implantation (Mishra and Seshagiri, 
2000), but becomes localized to the epithelium surrounding an implanted blastocyst late 
on day 4 of gestation (Wang et al., 2002). 
Several lines of investigation suggest that embryo-derived HBEGF is at least one 
of the signals that direct peri-implantation expression of HBEGF in the uterus.  Indeed, 
mouse and hamster blastocysts express HBEGF (Hamatani et al., 2004; Leach et al., 
2004a; Wang et al., 2002).  Further confirmation comes from an experiment using 
beads coated with HBEGF that were placed in the uterus of pseudopregnant mice 
mated with vasectomized males (Paria et al., 2001).  In this experiment, the HBEGF 
specifically induced endogenous uterine HBEGF gene expression, along with a local 
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increase in vascular permeability and decidualization, comparable to changes arising 
from the presence of a blastocyst (Paria et al., 2001).  Experiments using HBEGF-
coated beads suggest that HBEGF produced by embryos induces the molecular and 
physiological changes in the uterus. These findings support the hypothesis that cross 
talk mediated temporally by HBEGF occurs between embryonic and maternal tissues in 
rodents. Its expression in the early preimplantation blastocyst (Leach et al., 2004a; 
Wang et al., 2002) implies that trophectoderm-derived HBEGF could initially induce 
uterine HBEGF expression, along with other decidualization-related changes. 
Subsequently, uterine HBEGF secretion could advance trophoblast differentiation to an 
invasive phenotype and augment implantation. Additional work is required to distinguish 
the contribution of HBEGF from both of these sources and substantiate this hypothesis. 
Evidence that HBEGF can advance the developmental program of the blastocyst 
is abundant and suggests that reciprocal signaling could exist between the embryo and 
uterus. Exogenous application of recombinant HBEGF matures rodent blastocysts in 
vitro, augmenting their ability to hatch from the zona pellucida, and accelerating 
trophoblast differentiation and adhesion competency (Das et al., 1994c; Wang et al., 
2000).  HBEGF increases the rate of hamster blastocyst hatching, adhesion 
competency, and trophoblast outgrowth (Mishra and Seshagiri, 2000; Seshagiri et al., 
2002) and augments development of 8-cell rat embryos to the blastocyst stage 
(Tamada et al., 1999).  Intraluminal injection of HBEGF induces implantation of rat 
embryos in a delayed implantation model (Tamada et al., 1999).  Moreover, exposure of 
mouse embryos to HBEGF during culture before transferring blastocysts to the uterus 
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significantly increases the number of implantation sites that eventually form (Lim et al., 
2006).   
In mice, HER4 trafficks to the trophectoderm surface late on day 4 and is a 
prerequisite for HBEGF signaling that accelerates trophoblast development (Wang et 
al., 2000).  HBEGF can then bind HER1 and HER4 (preferentially to HER4) on the 
surface of mouse blastocysts in a HSPG-dependent fashion, leading to HER 
autophosphorylation (Das et al., 1994a; Lim et al., 2006; Paria et al., 1999; Wang et al., 
2000).  Lysophosphatidic acid also accelerates trophoblast outgrowth, and does so by 
transactivating HER1 and HER4 through Ca2+-dependent HBEGF trafficking and 
shedding (Leach et al., 2004a). Cross-talk with other signaling pathways that advance 
blastocyst differentiation could similarly target HBEGF shedding to transactivate HER 
kinases.  HBEGF signaling accelerates mouse blastocyst differentiation to an adhesive 
phenotype via Ca2+ influx through N-type voltage-gated channels and activation of 
protein kinase C and calmodulin (Wang et al., 2000).  This signaling pathway induces 
trafficking of the integrin α5 subunit to the surface of trophectoderm cells where it 
mediates strong adhesion to fibronectin (Armant, 2005; Wang et al., 2000).     
In addition to its ability to advance hatching and trophoblast differentiation, 
proHBEGF could directly mediate attachment of the trophectoderm to the luminal 
surface of the endometrium (Fig. 1.2).  Cells engineered to express proHBEGF bind to 
day 4 mouse blastocysts, but not to delayed blastocysts (Raab et al., 1996), suggesting 
that proHBEGF, by binding to its receptors, is capable of supporting the attachment 
reaction during implantation. Binding between these cells and normal day 4 blastocysts 
is blocked by treating the blastocysts with heparinase or a synthetic peptide   
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corresponding to the HSPG-binding domain of HBEGF (Raab et al., 1996).  
Furthermore, its potential binding partners HSPG, HER1 and HER4 are downregulated 
during delayed implantation, and are coordinately upregulated with HBEGF during 
activation with E2 (Paria et al., 1993; Paria et al., 1999; Smith et al., 1997).  These 
reports provide intriguing information about the elusive mechanisms underlying 
diapause. 
Humans 
In contrast to the rodent endometrium, which may require stimulation from an 
embryo for HBEGF expression (Paria et al., 2001), HBEGF expression in the human 
endometrium precedes the appearance of the blastocyst (Leach et al., 1999b). As in 
other species, HBEGF can simultaneously function during human implantation as an 
attachment factor and a growth factor.  In humans, HBEGF, HER1 and HER4 are 
present in peri-implantation blastocysts with HER4 more prominent in the 
trophectoderm (Chobotova et al., 2002b).  This suggests that HBEGF present on the 
endometrium might bind its receptors on an apposed blastocyst, and vice versa.  
Indeed, mature human blastocysts adhere to immobilized proHBEGF, an interaction 
that is competitively inhibited by addition of sHBEGF (Chobotova et al., 2002b).  Similar 
results were obtained when human blastocysts were applied to a fixed monolayer of 
CHO cells overexpressing proHBEGF. As a growth factor, HBEGF accelerates 
development of human embryos to the blastocyst stage and their subsequent hatching 
from the zona pellucida (Martin et al., 1998b; Sargent et al., 1998).  While LIF can only 
induce development of embryos up to the blastocyst stage, HBEGF influences their 
maturation at least through the hatching stage (Sargent et al., 1998).  Although these 
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studies are instructive, it remains to be demonstrated whether these diverse functions of 
HBEGF are imperative in vivo.     
1.3. The Role of HBEGF in Human Placentation 
HBEGF is present throughout the course of human gestation.  It is abundant in 
1st trimester decidua, and in placental tissue during all three trimesters (Birdsall et al., 
1996), though its presence in the syncytiotrophoblast (STB) layer is weak in first 
trimester placentas (Yoo et al., 1997a).  HBEGF is also expressed in villous and 
extravillous cytotrophoblast (CTB) from Weeks 14-35 in normal placentas and those 
delivered pre-term (Leach et al., 1999b; Leach et al., 2002a).  Several members of the 
EGF family and HER tyrosine kinases are expressed in placental trophoblast 
populations (Hofmann et al., 1992; Tanimura et al., 2004), indicating that the EGF 
signaling system is active during placental development. 
Structure of the Early Placenta 
 As trophoblasts begin to invade into the endometrium, they differentiate along 
two paths (Hunkapiller and Fisher, 2008; Morrish et al., 1998).  CTBs are highly 
proliferative, mononuclear cells that can fuse to form multinucleated STB cells.  The 
STB initially invades into the endometrium. At the periphery of the conceptus, the 
chorionic villi emerge with a vascularized mesenchymal core and a stratified epithelium 
composed of CTB and an outer layer of STB. The STB transports nutrients, gases and 
waste products between the maternal blood and fetal blood in capillaries of the 
chorionic villi.  A few weeks after implantation, anchoring villi appear at the surface of 
the endometrium (decidua basalis) as CTBs penetrate through the STB layer and 
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assemble into dense cellular columns.  The most distal CTBs differentiate to an 
extravillous phenotype that invades interstitially.  Upon reaching uterine blood vessels, 
the CTBs invade and remodel them, converting the spiral arteries into highly dilated 
vessels (Pijnenborg et al., 1983a). Endovascular trophoblast cells produce proteins 
characteristic of endothelial cells in a process known as pseudovasculogenesis 
(Blankenship and Enders, 1997; Zhou et al., 1997a; Zhou et al., 1997b).  Invasive CTBs 
remodel the maternal spiral arteries into permanently dilated structures as far as the first 
third of the myometrium (Pijnenborg et al., 1983a). Maternal blood is thus directed to the 
intervillous space at increased flow rates (Hunkapiller and Fisher, 2008).  As 
trophoblasts differentiate to extravillous and endovascular phenotypes, they undergo a 
process known as integrin-switching in which differentiation is accompanied by changes 
in expression of adhesion molecules (Damsky et al., 1994; Zhou et al., 1997a; Zhou et 
al., 1997b).  Different integrins mediate attachment, invasion, and vascular remodeling.  
For example, ITGA6/ITGB4 is expressed by non-motile villous CTBs, while invasive 
interstitial trophoblast cells express ITGA1/ITGB1.  CTBs of the columns in anchoring 
villi express α5β1 with differing levels of the other two integrins, depending on whether 
they have a proximal or distal position within the anchoring villi (Damsky et al., 1994).  
Primary CTB cultures from 1st trimester placentas undergo integrin switching during 
extravillous differentiation on Matrigel basement membrane, providing a useful 
experimental model. 
Challenges of the Maternal Environment 
 Blastocyst implantation takes place in a uterine environment low in O2 (~18 mm 
Hg or 2%), a condition that appreciably changes (~60 mm Hg or 8%) only after the 10th 
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week of gestation (Burton and Jauniaux, 2004; Burton et al., 1999; Jauniaux et al., 
2001b; Rodesch et al., 1992).  Prior to the 10th week, invading endovascular 
trophoblasts occlude maternal blood vessels, leaving the intervillous space relatively 
hypoxic.  Human trophoblast cells are programmed to function under these conditions, 
and, in fact, proliferate at higher rates when cultured at 2% O2 (Genbacev et al., 1996b; 
Genbacev et al., 1997b).  Furthermore, localized areas within the placenta are 
temporarily exposed to oxygenated maternal blood during this early developmental 
period, but they are able to survive these reoxygenation episodes (Hung and Burton, 
2006).  Perhaps more profound is the extensive introduction of fully oxygenated 
maternal blood that occurs around Week 10 as trophoblastic plugs become dislodged.  
The placental unit normally survives this insult and trophoblast invasion continues into 
the second trimester (Norwitz et al., 2001).  Elevation of O2 leads to free radical 
production, and evidence suggests that excessive oxidative stress may precipitate 
placental pathologies such as preeclampsia (Hung and Burton, 2006).  Free radicals are 
normally deactivated in the placenta by xanthine dehydrogenase/xanthine oxidase, 
which is elevated in placentas during labor, when there is an abundance of local O2 
fluctuations (Many and Roberts, 1997).  Clearly, mechanisms exist that protect 
trophoblasts from erratic O2 levels. 
HBEGF Mediates Trophoblast Motility and Survival 
HBEGF stimulates trophoblast invasion from first trimester chorionic villous 
explants cultured on Matrigel basement membrane, but has little effect on CTB cell 
proliferation (Leach et al., 2004a).  As gestation progresses, there is a decrease in 
trophoblast capacity to differentiate along the extravillous pathway (Damsky et al., 1994; 
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Librach et al., 1991). EGF augments the invasiveness of cultured first trimester CTBs, 
but with less effectiveness when CTBs are obtained later in gestation (Bass et al., 
1994b).  In HT-H cells (human embryonal carcinoma that spontaneously differentiate 
into trophoblasts), induction of HER1 phosphorylation by EGF or HBEGF requires 
derepression of the receptor by trophinin (Sugihara et al., 2007), a transmembrane 
protein expressed in both human trophoblasts and the uterine epithelium that is capable 
of mediating cell adhesion through homodimerization (Suzuki et al., 1999). When 
ligated, trophinin interaction with the cytoplasmic protein bystin is disrupted, releasing 
bystin inhibition of HER autophosphorylation (Sugihara et al., 2007).  Therefore, HBEGF 
can activate HER downstream signaling only when opposing trophinin proteins are 
engaged by opposing cells. The relationship between the trophinin and EGF signaling 
systems could be particularly important for trophoblast invasive differentiation during 
blastocyst implantation.  
Cell lines generated from immortalized human cytotrophoblasts have proven to 
be highly useful for experimental investigation of implantation and early placentation. 
HTR-8/SVneo cells are an immortalized human CTB cell line originating from first 
trimester villous explants that characteristically secrete chorionic gonadotropin and 
become invasive in conjunction with appropriate integrin switching and upregulation of 
HLA-G (Graham et al., 1993b; Kilburn et al., 2000b).  Therefore, HTR-8/SVneo cells 
closely resemble the primary CTB cells from which they are derived, providing a robust 
experimental model.  HBEGF, EGF, and TGFA each induce integrin-switching in HTR-
8/SVneo cells by signaling through HER1 or HER4 to increase the α1 integrin subunit 
and decrease α6 (Leach et al., 2004a).  As a result, there is an increase in trophoblast 
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cell migration and invasive activity (Fig. 1.3).  The extensive expression of HBEGF in 
trophoblasts, particularly within extravillous populations (Leach et al., 2002a), could be 
vital for their invasive activities during the establishment of pregnancy and physiological 
conversion of spiral arteries. As gestation continues and trophoblasts loose their 
capacity for extravillous differentiation (Damsky et al., 1994; Librach et al., 1991), the 
involvement of HBEGF and the EGF signaling system in trophoblast invasion wanes 
(Bass et al., 1994b). However, other roles for HBEGF could come into play late in 
gestation. 
In vivo, placentation initiates in a relatively low O2 environment.  Although CTBs 
proliferate faster at low O2 concentrations, invasion is more aggressive at higher O2 
(Genbacev et al., 1996b; Genbacev et al., 1997b).  Therefore, pseudovasculogenesis is 
initially moderate, and rapid CTB growth leads to occlusion of the spiral arteries.  It has 
not been clear how trophoblast tissues survive during this hypoxic phase.  We have 
observed that HBEGF, but not other EGF family members, is upregulated in the HTR-
8/SVneo CTB cell line when exposed to 2% O2 (Armant et al., 2006).  Using specific 
antagonists of HBEGF signaling, it can be demonstrated that HBEGF inhibits apoptosis 
due to low O2, but has no effect on proliferation rates enhanced by low O2.  This study 
also established that cytoprotection requires metalloproteinase shedding of HBEGF and 
binding to either HER1 or HER4 (Fig. 1.4 A).  Quantification of mRNA and protein levels 
indicated that HBEGF increases 100-fold through a post-transcriptional mechanism.  
Antagonizing HBEGF signaling prevents its upregulation, suggesting that low levels of 
resident proHBEGF are cleaved through activation of metalloproteinases in low O2 to  
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initiate its synthesis downstream of HER kinases.  A recent study suggests that ADAM-
17 may be responsible for initiating this signaling event in vivo (Hung et al., 2008).  
Further studies are needed to determine which metalloproteinases are directly 
responsible for HBEGF shedding in trophoblast cells.  In contrast to 1st trimester CTBs, 
trophoblasts in villous explants from term placentas do not elevate HBEGF levels in 
response to low O2 and their survival is compromised by low O2 (Imudia et al., 2008).  
However, addition of HBEGF to term villous explants cultured at 2% O2 inhibits 
trophoblast apoptosis, demonstrating its persistent role as a survival factor. These 
findings highlight the importance of HBEGF in the success of early placentation and in 
protecting trophoblast cells from the damaging effects of low O2 encountered throughout 
gestation.   
Using placental villous explants, Hung et al demonstrated that reactive oxygen 
species are generated in an in vitro reoxygenation injury model (Hung et al., 2001b), 
leading to apoptosis of the trophoblasts (Hung et al., 2002b).  HBEGF can prevent 
apoptosis induced by reoxygenation injury in HTR-8/SVneo cells (Fig. 1.4 B) by 
signaling through its receptors, HER1 and HER4 (Leach et al., 2008a).  Although 
HBEGF is downregulated within 30 min of elevating the O2 concentration from 2% to 
20%, accumulated sHBEGF generated by trophoblasts at low O2 may protect against 
sudden exposure to oxygenated maternal blood in the uterine environment.  Ethanol, a 
teratogenic substance with oxidative qualities, also induces apoptosis in HTR-8/SVneo 
cells (Wolff et al., 2007).  When HTR-8/SVneo cells are exposed to ethanol and HBEGF 
together, apoptosis is inhibited in a HER1- or HER4-dependent fashion.  During both 
reoxygenation injury and ethanol exposure, other members of the EGF family are 
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cytoprotective to varying degrees (Leach et al., 2008a; Wolff et al., 2007).  In contrast, 
only HBEGF inhibits apoptosis in CTBs cultured at low O2 (Armant et al., 2006).  It has 
been proposed that insults such as reoxygenation injury are not always tolerated and 
can lead to placental pathologies (Hung and Burton, 2006).  The activity of the EGF 
signaling system could be a critical variable that keeps oxidative stress in check. 
Clinical Considerations 
Heparin has long been used to treat pregnant women with certain thrombophilias 
(Greer, 2003), but its impact on trophoblasts has only recently been investigated.  Since 
heparan sulfate is an obligate cofactor for HBEGF, clinical application of heparin during 
pregnancy could influence the activity of this growth factor.  Indeed, unfractionated 
heparin inhibits apoptosis induced by diverse signals in 1st trimester cytotrophoblast 
cells (Hills et al., 2006).  The same downstream signaling pathways activated by 
heparin were also induced by treating the cells with HBEGF.  It could be speculated that 
addition of its cofactor activates HBEGF in trophoblasts to enhance survival.  On the 
other hand, fractionated heparin, also used as an anticoagulant, suppresses the 
invasive capacity of primary extravillous trophoblasts (Ganapathy et al., 2007).  This 
suggests that there could be clinical advantages to using unfractionated heparin over 
fractionated heparin. 
A pathological reduction of HBEGF expression is observed in placentas of 
patients with the hypertensive syndrome preeclampsia (Leach et al., 2002a), which is 
associated with decreased trophoblast invasion (Brosens et al., 1972b) and increased 
levels of trophoblast apoptosis (Allaire et al., 2000a; DiFederico et al., 1999b).  This 
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finding led us to hypothesize that dysregulation of HBEGF and the resulting deficiencies 
in trophoblast function could contribute to preeclampsia, although it remains to be 
determined when during the course of gestation HBEGF levels are first reduced in 
preeclamptic pregnancies.  Trophoblast invasion is shallow in preeclampsia possibly 
due to a lack of HBEGF-induced cell migration and a rise in apoptosis, exacerbated by 
reduced cytoprotection.  The increased oxidative damage to trophoblast cells (Redman 
and Sargent, 2005) and the paucity of HBEGF in preeclamptic placentas is consistent 
with the hypothesis that HBEGF performs an important role as a survival factor 
throughout gestation. Patients delivering preterm without hypertensive disorder produce 
placentas with high levels of HBEGF (Leach et al., 2002a). However, there was an 
intermediate reduction of HBEGF in extravillous trophoblasts for those women who 
delivered small for gestational age infants. Intrauterine growth restriction, like 
preeclampsia, has been linked to aberrant trophoblast invasion (Khong et al., 1986) and 
elevated apoptosis (Ishihara et al., 2002), suggesting shared elements in the etiology of 
both disorders. Premature placental perfusion in preeclamptic pregnancies (Jauniaux et 
al., 2003) could induce apoptosis by stressing trophoblast cells before HBEGF has 
sufficiently accumulated during the early hypoxic period. Because there are varying 
levels of severity of placental reoxygenation, it has been hypothesized that 
preeclampsia may be the result of sub-lethal levels of reoxygenation, leading to 
abnormal placentation, whereas more pronounced reoxygenation will terminate the 
pregnancy (Leach et al., 2008a).  More work is needed to determine if the etiology of 
this disease involves a lack of HBEGF production by trophoblasts or the activity of 
factors that suppress HBEGF signaling. 
	   24 
1.4. Looking Ahead 
HBEGF performs numerous functions during pregnancy that are conserved 
across mammalian species with divergent reproductive physiologies.  In addition to 
preparing both the preimplantation embryo and uterus for their mutual interaction, 
HBEGF appears to directly facilitate the process of implantation. As development 
proceeds, HBEGF provides a stimulus for trophoblast invasion and serves as a critical 
survival factor in an environment subject to wide swings in oxygenation. Due to its roles 
in trophoblast cell differentiation and survival, dysregulation of HBEGF could have 
profound consequences, from complete pregnancy failure to the onset of obstetrical 
disorders.  The association of its deficiency with preeclampsia is consistent with a 
critical role for HBEGF in human placentation. New insights into the contribution of 
HBEGF to placentation could be obtained with the mouse model, which has not been 
exploited. HBEGF-deficient transgenic embryos develop to term with heart defects 
(Iwamoto et al., 2003; Jackson et al., 2003), but this system has not been examined in 
depth for errors in placentation due to the absence of HBEGF. Additionally, the immune 
system undergoes unique changes during pregnancy that include tolerance of the fetal-
maternal allograft and the recruitment of uterine natural killer cells, macrophages and 
dendritic cells to the implantation site. It is currently thought that these cells ensure 
proper implantation and that trophoblast cells help to orchestrate their immune function 
(Mor, 2008). However, the role of HBEGF in the trophoblast-immune relationship during 
pregnancy remains unexplored.  
Tissue-specific differences in HBEGF function could stem from the 
microenvironment near targeted cells. Expression of its cofactor, HSPG, varies among 
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cells and with differentiation.  Other growth factors, such as LIF, can profoundly affect 
HBEGF expression, as seen in the peri-implantation uterus.  HBEGF forms complexes 
with other transmembrane proteins, including CD9 and ITGA3/ITGB1 (Raab and 
Klagsbrun, 1997), but the relevance of these interactions for implantation and 
placentation has not been investigated. There is a need for better understanding of the 
molecular interactions that regulate HBEGF expression, as well as the genes induced 
by HBEGF in reproductive tissues.  
The ability of HBEGF to regulate diverse outcomes is not well understood.  
Autocrine regulation of HBEGF is post-transcriptional in CTBs cultured at reduced O2 
levels (Armant et al., 2006).  One possibility is that HBEGF signaling releases its own 
message from translational repression.  Maintenance of a dormant, stable HBEGF 
mRNA pool could provide a reserve for rapid mobilization during episodes of hypoxia 
without a high cost in energy.  Although the exact nature of this post-transcriptional 
regulation is not yet understood, it would be useful to know whether HBEGF signaling 
similarly targets other proteins for synthesis. Finally, an examination of the intracellular 
circuitry downstream of the HER kinases activated by HBEGF will be important for 
clarifying the molecular basis of its varied functions. 
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CHAPTER 2. Function-Specific Intracellular Signaling Pathways Downstream of 
Heparin-Binding EGF-like Growth Factor Utilized by Human Trophoblasts 
SUMMARY 
Heparin-binding EGF-like growth factor (HBEGF) is expressed by trophoblast 
cells throughout gestation. First trimester cytotrophoblast cells are protected from 
hypoxia-induced apoptosis due to the accumulation of HBEGF through a post-
transcriptional autocrine mechanism. Exogenous application of HBEGF is cytoprotective 
in a hypoxia/reoxygenation (H/R) injury model and initiates trophoblast extravillous 
differentiation to an invasive phenotype. The downstream signaling pathways induced 
by HBEGF that mediate these various cellular activities were identified using two human 
first-trimester cytotrophoblast cell lines, HTR-8/SVneo and SW.71, with similar results.  
Recombinant HBEGF (1 nM) induced transient phosphorylation of MAPK3/1 (ERK), 
MAPK14 (p38) and AKT within 15 minute, and JNK after 1-2 h. To determine which 
downstream pathways regulate the various functions of HBEGF, cells were treated with 
specific inhibitors of the ERK upstream regulator MEK (U0126), the AKT upstream 
regulator phosphoinositide-3 (PI3)-kinase (LY294002), MAPK14 (SB203580) and JNK 
(SP600125), as well as with inactive structural analogues.  Only SB203580 specifically 
prevented HBEGF-mediated rescue during H/R, while each inhibitor attenuated 
HBEGF-stimulated cell migration. Accumulation of HBEGF at reduced O2 was blocked 
only by a combination of U0126, SB203580 and SP600125.  We conclude that HBEGF 
advances trophoblast extravillous differentiation through coordinate activation of PI3 
kinase, ERK, MAPK14 and JNK, while only MAPK14 is required for its anti-apoptotic 
activity.  Additionally, low O2 induces an autocrine increase in HBEGF protein levels 
through MAPK14, JNK or ERK. These experiments reveal a complexity of the 
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intracellular signaling circuitry that regulates trophoblast functions critical for 
implantation and placentation. 
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INTRODUCTION 
 Blastocyst implantation is a tightly regulated and dynamic process that 
establishes a pregnancy.  Central to implantation are the trophoblast cells that populate 
the exterior of the blastocyst. These unique cells invade the endometrium interstitially 
and intravascularly (Pijnenborg et al., 1981), and can survive the changes in O2 
concentration that accompany early development of the placenta (Burton and Jauniaux, 
2004). Early in this process, trophoblast cells function in a relatively hypoxic uterine 
environment, a condition that is drastically altered during the 10th week of pregnancy in 
humans when extravillous trophoblast cells occluding the maternal arteries dislodge, 
allowing highly oxygenated blood to enter the intervillous space within the developing 
placenta. Trophoblasts survive this oxidative challenge, and accelerate the pace of 
invasion (Norwitz et al., 2001). Oxygen fluctuations occur throughout pregnancy with 
great variation among individuals (Burton and Jauniaux, 2004). The elevation of O2 after 
an ischemic episode can damage trophoblast cells due to the resulting oxidative stress 
(Hung et al., 2001a), possibly precipitating pathological outcomes (Hung et al., 2002a). 
The epidermal growth factor (EGF) signaling system is capable of regulating 
diverse cellular activities, including survival, invasion and differentiation (Holbro and 
Hynes, 2004a; Riese and Stern, 1998).  EGF-related growth factors are expressed 
abundantly in the receptive endometrium (Hofmann et al., 1991; Horowitz et al., 1993), 
with heparin-binding EGF-like growth factor (HBEGF) having a prominent role during 
peri-implantation development (Leach et al., 1999a; Lessey et al., 2002b; Yoo et al., 
1997b). It is specifically expressed at the site of blastocyst attachment in mice, 
immediately prior to implantation (Das et al., 1994b), and appears cyclically in humans 
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at the apical surface of luminal epithelial cells during the period when the endometrium 
is most receptive for embryo implantation (Leach et al., 1999a). Conditional excision of 
HBEGF in the murine uterus delays blastocyst implantation and reduces litter sizes (Xie 
et al., 2007), suggesting that HBEGF is important not only for timely attachment of the 
blastocyst, but also for subsequent invasive events. Indeed, HBEGF accelerates the 
differentiation of mouse trophoblast cells to an adhesive phenotype (Wang et al., 2000), 
increasing the area over which they subsequently migrate (Das et al., 1994b). Similar 
stimulatory effects of HBEGF have been reported for human embryos (Martin et al., 
1998a). HBEGF is implicated in both the successful invasion and survival of human 
cytotrophoblast cells (Armant et al., 2006; Leach et al., 2008a; Leach et al., 2004b). 
Members of the EGF family, including HBEGF, EGF and TGFA, are capable of inducing 
altered integrin expression and accelerating trophoblast migratory and invasive activity 
in first trimester human cytotrophoblast cells (Bass et al., 1994a; Leach et al., 2004b). 
EGF is capable of preventing cytokine-induced apoptosis in term cytotrophoblast and 
syncytiotrophoblast (Garcia-Lloret et al., 1996; Smith et al., 2002) and both EGF 
(Mackova et al., 2003) and HBEGF (Imudia et al., 2008) block apoptosis resulting from 
exposure to low O2. During the first trimester, trophoblast cells have the ability to survive 
and proliferate in the very low O2 environment present at the implantation site 
(Genbacev et al., 1996a; Genbacev et al., 1997a). Investigation of their survival 
capacity revealed cytoprotective activity provided as HBEGF accumulates in 
cytotrophoblast cells when exposed to low O2 tension (Armant et al., 2006).  
Failure of trophoblast cells to survive and invade maternal tissues interferes with 
the remodeling of uterine spiral arteries required to increase blood flow to the growing 
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conceptus and is thought to contribute to preeclampsia (Allaire et al., 2000b; Brosens et 
al., 1972a; DiFederico et al., 1999a), intrauterine growth restriction (Ishihara et al., 
2002; Khong et al., 1986) and spontaneous abortion (Burton and Jauniaux, 2004). The 
physiological interaction of trophoblast cells with O2 during pregnancy is complex, with a 
preference for low levels during the first trimester. It has been hypothesized that 
fluctuations in O2 during early pregnancy create hypoxia/reoxygenation (H/R) episodes 
that produces oxidative stress, which may compromise trophoblast survival (Hung and 
Burton, 2006; Hung et al., 2001a; Hung et al., 2002a). Indeed, activation of the EGF 
signaling system with HBEGF or related growth factors can prevent apoptosis due to 
oxidative stress caused by exposing first trimester cytotrophoblast cells to H/R (Leach et 
al., 2008a). Examination of placentas delivered by women with preeclampsia reveals a 
dramatic reduction in HBEGF expression (Leach et al., 2002b) and suggests the 
important role of this signaling system.  
Though HBEGF appears to have many important functions in trophoblast cells, 
the underlying mechanisms have not yet been assessed.  To this end, we have initiated 
experiments to identify intracellular signaling pathways that are responsible for the 
multiple outcomes of HBEGF signaling. Using two immortalized, human, first trimester 
cytotrophoblast cell lines, we have examined the downstream signaling circuitry that 
regulates the ability of HBEGF to autoregulate, induce migration and inhibit apoptosis. 
As with all EGF family ligands, HBEGF initially binds to and activates members of the 
HER/ERBB receptor tyrosine kinase family (Holbro and Hynes, 2004a; Riese and Stern, 
1998). EGFR, ERBB2, ERBB4 (HERs 1, 2 and 4), but not ERBB3 (HER3), possess 
functional intracellular tyrosine kinase activities that, upon ligation and dimerization, 
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induce cross phosphorylation of their intracellular domains.  Phosphorylated tyrosine 
residues then serve as docking sites for intracellular proteins that direct downstream 
signaling pathways, including phosphoinositide-3-kinase (PIK3) and MAPK cascades.  
Using inhibitors of the most common MAPK pathways and PIK3, we have examined 
their roles downstream of HBEGF in trophoblast cell extravillous differentiation, survival, 
and in the upregulation of HBEGF at low O2. 
	   32 
MATERIALS & METHODS 
Cell Culture & Reoxygenation Injury 
Two immortalized, first trimester, human cytotrophoblast cell lines, HTR-8/SVneo 
(Graham et al., 1993a) and SW.71 (Aplin et al., 2006), were cultured at 2% or 20% O2, 
as previously described (Leach et al., 2008a; Leach et al., 2004b). The HTR-8/SVneo 
cell line originates from first trimester villous explants and is immortalized by stably 
expressing the large T viral antigen (Graham et al., 1993a).  The SW.71 cell line also 
originates from first trimester villous explants, but is immortalized by over expressing the 
telomerase enzyme (Aplin et al., 2006).  SW.71 cells resemble extravillous trophoblasts, 
including their expression of human chorionic gonadotropin (hCG), vimentin, 
cytokeratin-7, and their invasion of Matrigel. 
Exposure to H/R has been previously described (Leach et al., 2008a). Briefly, 
cells were cultured at 2% O2 for 2 hours and then media was replaced with fresh media 
pre-equilibrated at 20% O2 for an additional 6 hours of culture at 5% CO2 and ambient 
O2.  Cells cultured at 2% O2 for 8 hours served as a control.  Where indicated, cells 
were cultured in the presence of 1 nM recombinant human HBEGF (R&D Systems, 
Minneapolis, MN) with or without addition of inhibitors.  Inhibitors and their inactive 
structural analogs (Table 2.1 (Bennett et al., 2001; Favata et al., 1998; Klutchko et al., 
2006; Lee et al., 1994; Mitamura et al., 1995; Vlahos et al., 1994)) were purchased from 
Calbiochem (EMD, Carlsbad, CA) and were specific for JNK (JNK Inhibitor II and 
negative control), MAPK14 (p38) (SB203580 and SB202474), PIK3 (PI3K) (LY294002 
and LY303511), and MEK (U0126 and U0124).  Inhibitors of EGFR/ERBB2/ERBB4  
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Table 2.1. Inhibitors and inactive structural analogs used in this study 
(ERBB/HER Inhibitor) tyrosine kinase activity (cat. #324840) and HBEGF signaling 
(cross-reacting material 197; CRM197) were also purchased from Calbiochem. 
!
Inhibitor Target Chemical Structure IC50 
Working 
Conc. 
ERBB/HER 
Inhibitor 
ERBB1 
ERBB2 
ERBB4 
N-(4-((3-Chloro-4-
fluorophenyl)amino)pyrido[3,4-
d]pyrimidin-6-yl)2-butynamide 
1 nM 10 nM 
CRM197 HBEGF CRM197 is a nontoxic diphtheria 
toxin with a G52E point mutation 
 10 µg/mL 
U0126 MEK 1,4-diamino-2,3-dicyano-1,4-bis(2-
aminophenylthio)butadiene 
75 nM 1 µM 
U0124 Control 1,4-diamino-2,3-dicyano-1,4-
bis(methylthio)butadiene 
> 100 µM 1 µM 
SP600125 JNK 1,9-pyrazoloanthrone 100 nM 1 µM 
JNK Control Control N!-Methyl-1,9-pyrazoloanthrone 20 µM 1 µM 
SB203580 p38 4-(4-fluorophenyl)-2-(4-
methylsulfonylphenyl)-5-(4-
pyridyl)1H-imidazole, HCl 
600 nM 1 µM 
SB202474 Control 4-ethyl-2(p-methoxyphenyl)-5-(4!-
pyridyl)-IH-imidazole 
 1 µM 
LY 294002 PI3K 2-(4-Morpholinyl)-8-phenyl-4H-1-
benzopyran-4-one 
1.4 µM 10 µM 
LY 303511 Control 2-Piperazinyl-8-phenyl-4H-1-
benzopyran-4-one 
> 100 µM 10 µM 
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Cell Death Assay 
Cells fixed with 4% paraformaldehyde for 20 minutes were permabilized with 
0.1% Triton-X100 for 15 minues and terminal deoxynucleotidyl transferase-mediated 
deoxyuridine 5-triphosphate nick end-labeled (TUNEL) using a kit from Roche Applied 
Science (Indianapolis IN), as previously described (Armant et al., 2006).  Briefly, cell 
nuclei were counterstained with 1 mg/ml DAPI to obtain a “TUNEL Index” by calculating 
a ratio of TUNEL-positive nuclei to DAPI-positive nuclei.  Previously, we determined that 
cell death in cytotrophoblast exposed to H/R or low O2 alone in the absence of HBEGF 
signaling was due to apoptosis rather than necrosis (Armant et al., 2006; Leach et al., 
2008a). 
Migration Assay 
 A modified Boyden chamber assay was conducted using sterile transwell inserts 
with polycarbonate membrane filters containing 8-mm pores (Corning) to examine the 
extravillous differentiation of trophoblast cells to a migratory phenotype. Transwell 
inserts were coated top and bottom with 10 µg/mL human plasma fibronectin 
(Invitrogen) in sterile PBS at 4°C overnight. Fibronectin was removed from each well 
and 500 µL of pre-warmed serum-free media was added to the lower chamber. 
Treatments were carried out prior to conducting the migration assays. For each 
treatment, cells were first serum-starved for 24 hours by culturing in DMEM/F-12 
containing 5 mg/mL BSA. Media was then either exchanged for fresh serum-free media 
(vehicle control) or serum-free media containing 10 nM recombinant HBEGF without 
(positive control) or with (experimental groups) inhibitor. After 4 hours of culture, cells 
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were washed twice with 2 mL of serum-free media and culture was continued for an 
additional 20 hours. After their pretreatments, 50,000 cells were added to the upper 
chamber of triplicate transwell insert in a final volume of 200 µL. Transwell plates were 
incubated at 37°C for 9 hours. Cells migrating to the underside of the membrane were 
trypsinized into the lower well, combining with cells that had detached from the 
underside of the membrane during culture. The cells were fixed with 10% formalin and 
mixed by pipetting. After allowing the cells to settle for 15 min, they were counted using 
a phase-contrast inverted light microscope at 100x, viewing 10 different fields in each 
well.  From the average number of cells per field, the total number of cells in the lower 
well was calculated. 
Western Blotting 
Western blots were performed as previously described (Kilburn et al., 2000a). 
Cellular lysates were diluted in SDS sample buffer containing 5% β-mercaptoethanol, 
run on precast 4-20% Tris-HCl gradient gels (BioRad, Hercules, CA) and blotted with 
primary antibodies.  Antibodies against AKT1/2/3 (monoclonal rabbit), phospho-
AKT1/2/3 (pAKT; Ser473; monoclonal rabbit), JNK1/2/3 (polyclonal rabbit), phospho-
JNK1/2/3 (pJNK; Thr183/Tyr185; monoclonal mouse), MEK1/2 (polyclonal rabbit), and 
phospho-MEK1/2 (pMEK; Ser217/221; polyclonal rabbit) were purchased from Cell 
Signaling Technologies (Beverly MA).  Antibodies against HBEGF (polyclonal goat), 
MAPK14 (polyclonal rabbit), phospho-MAPK14 (pMAPK14; Thr180/Tyr182; polyclonal 
rabbit), MAPK3/1 (ERK; monoclonal mouse), and phospho-ERK (pERK; pERK1 at 
Thr202/Tyr204 and pERK2 at Thr185/Tyr187; monoclonal rabbit) were purchased from 
R&D Systems (Minneapolis, MN). Secondary anti-rabbit, anti-goat and anti-mouse 
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antibodies purchased from Cell Signaling Technologies were detected by enhanced 
chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ).  Bands were 
observed for HBEGF, MEK/pMEK, ERK/pERK, MAPK14/pMAPK14, AKT/pAKT, and 
JNK/pJNK at 19-22, 45, 40/45, 40/45, 60, and 46/54 kDa, respectively. 
Immunocytochemistry 
 Cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton-X100, 
and stained for the presence of HBEGF protein, as previously described (Kilburn et al., 
2000a; Leach et al., 2004b).  For secondary antibody labeling, a horseradish 
peroxidase-conjugated anti-mouse/anti-rabbit kit was used (Dako EnVision System-
HRP), as described by Armant et al. (2006).  Image analysis was performed according 
to published procedures (Leach et al., 2002b). 
ELISA 
 Enzyme-linked immunosorbent assays were carried out using the HBEGF 
DuoSet ELISA Development kit (R&D Systems), as previously described (Armant et al., 
2006; Leach et al., 2008a). The optical density of the final reaction product was 
determined at 450 nm using a programmable multiplate spectrophotometer (Power 
Wave Workstation, Bio-Tek Instruments, Winooski, VT) with automatic wavelength 
correction. 
Statistics 
All assays were performed in triplicate and all experiments were repeated at least 
3 times and are reported as mean ± s.e.m.  Statistical significance was determined at 
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p<0.05 by ANOVA with the Student-Newman-Keuls post hoc test, using SPSS version 
12.0 statistics software (SPSS, Chicago, IL). 
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RESULTS 
HBEGF activates multiple signaling pathways 
 In order to identify signaling pathways targeted by HBEGF in human 
cytotrophoblast cell lines, cells were treated for 15 minutes to 1 hour with 10 nM 
recombinant HBEGF.  After 15 minutes, western blotting and immunocytochemistry 
revealed a marked phosphorylation of MAPK14, ERK and AKT (Fig. 2.1 and Fig. 2.2, 
respectively).  Phosphorylation was maintained for at least 45 minutes during treatment 
with HBEGF, then declined to levels observed before treatment.  Phosphorylation of 
JNK, however, was not significant after 1 hour of HBEGF treatment, but occurred 
shortly thereafter and remained phosphorylated for up to 6 hours (Fig. 2.1 and Fig. 2.2).  
We conclude that HBEGF induces a rapid, transient activation of the MAPK14 and ERK 
and PIK3 pathways, but a slower or delayed activation of the JNK pathway, downstream 
of ERBB/HER receptor tyrosine kinases. 
The rapid phosphorylations of ERK, MAPK14 and AKT were each attenuated by 
an inhibitor of ERBB/HER tyrosine kinase (Table 1) in a dose-dependent manner (Fig. 
2.3 A), establishing that the activity of HBEGF was mediated through its cognate 
receptors.  If individual pathways were blocked with their respective inhibitor, HBEGF-
induced phosphorylation of the specific target kinase was blocked, but not the other 
kinases (Fig. 2.3 B-D).  To validate JNK inhibition, an inhibitor of JNK blocked its 
phosphorylation when induced by H/R injury (Fig. 2.3 E).  Treating with the inactive 
structural analogues of these inhibitors had no affect on the phosphorylation status of  
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any of the target proteins.  None of the treatments altered the total levels of any protein 
(data not shown). 
HBEGF induces differentiation using multiple signaling pathways 
 HBEGF has previously been shown to induce the extravillous differentiation of 
trophoblasts from first trimester villous explants as evidenced by an increase in cell 
migration (Leach et al., 2004b). Pharmacological inhibitors were used, with inactive 
structural analogues as controls (Table 2.1), to delineate the signaling pathways 
downstream of HBEGF that mediate this differentiation.  A 4 h treatment with HBEGF 
20 hours prior to assay was found in preliminary experiments (Fig. 2.4) to be optimal for 
stimulation of cell migration.  As displayed in Fig. 2.5, HBEGF induced an increase 
(p<0.05) in migration that was blocked by inhibiting either ERBB/HER tyrosine kinase 
activity or HBEGF signaling. When cells were cultured in the presence of HBEGF and 
an inhibitor of any of the three MAPK pathways (MAPK14, MEK, or JNK) or the PIK3 
inhibitor, the increase in migration was blocked (Fig. 2.5).  The inactive structural 
analogues of each inhibitor were without effect.  Therefore, all four pathways were 
utilized by HBEGF to initiate trophoblast extravillous differentiation. 
HBEGF prevents apoptosis using the MAPK14 pathway 
 It was recently reported that HBEGF prevents H/R-induced apoptosis in human 
cytotrophoblasts by signaling through its cognate receptors, EGFR and ERBB4 (Leach 
et al., 2008a). Cell death detected by TUNEL was found to be associated with several 
criteria for apoptosis. When trophoblast cells were exposed to H/R and monitored by 
TUNEL, there was a marked increase in apoptosis, as compared to cells cultured  
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continuously at 2% O2 (Fig. 2.6 and Fig. 2.7). Supplementation with recombinant 
HBEGF attenuated the increase in apoptosis.  To identify the pathways utilized by 
HBEGF to inhibit apoptosis, cells were cultured with pharmacological inhibitors of PIK3, 
MEK, MAPK14, JNK or their inactive structural analogues (Table 2.1).  Inhibition of 
MAPK14, but not the other kinases, blocked the cytoprotective effects of HBEGF during 
H/R injury (Fig. 2.6).  The inactive structural analog of the MAPK14 inhibitor had no 
effect.  We found using the same set of inhibitors that the MAPK14 pathway is also 
required for cytotrophoblast survival at 2% O2 (Fig. 2.8), having previously found that 
apoptosis is specifically prevented by autocrine HBEGF signaling at low O2 (Armant et 
al., 2006). Therefore, HBEGF signaling through the MAPK14 pathway appears to 
abrogate trophoblast apoptosis induced by H/R injury and low O2. 
Low O2 increases synthesis of HBEGF through autocrine induction of MAPK14, 
ERK or JNK 
 HBEGF cellular and secreted protein levels are significantly increased in 
cytotrophoblast cells after 4 hours of culture at 2% O2 (Armant et al., 2006), but the 
downstream pathways responsible for its upregulation have not been identified. Using 
the HBEGF-specific antagonist CRM197, it was confirmed by immunohistochemical 
staining of HBEGF that HBEGF signaling is required for its upregulation during 
exposure to low O2 (Fig. 2.9).  Individual inhibitors of downstream signaling pathways 
did not alter the increase in HBEGF observed at 2% O2 (data not shown), so 
cytotrophoblast cells were treated with combinations of the inhibitors during hypoxic 
culture. By treating with all possible combinations of inhibitors or inactive structural 
analogues, it was determined that the three MAPK pathways, but not PIK3, were each  
	   46 
 
 
 
	   47 
 
 
 
 
 
 
 
 
 
 
 
	   48 
 
 
 
 
 
	   49 
 
 
 
 
	   50 
capable of mediating the increase in HBEGF protein levels at 2% O2 (Fig. 2.9 and Fig. 
2.10). HBEGF accumulation was only prevented when all three MAPK inhibitors were 
simultaneously applied. These findings were confirmed by quantifying HBEGF 
concentrations in cell lysates and culture medium using a specific ELISA (Table 2.2). 
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Table 2.2.  ELISA quantification of HBEGF protein upregulation at 2% O2 in the 
presence of signaling inhibitors. Cellular HBEGF concentrations are reported in ng per 
mg of total protein. 
 
HTR-8/SVneo 
20% O2 2% O2 Fold-change 
Control 3.08 68.78 22.37 
ERK, p38, JNK 6.75 3.23 0.48 
3 Inactive Analogues 2.34 79.02 33.75 
ERK, p38, JNK, PI3K 1.65 2.40 1.46 
4 Inactive Analogues 2.03 74.60 36.77 
 
SW71 
 
20% O2 2% O2 Fold-change 
Control 1.04 88.20 84.99 
ERK, p38, JNK 1.80 0.77 0.46 
3 Inactive Analogues 1.09 60.91 55.72 
ERK, p38, JNK, PI3K 1.88 0.87 0.46 
4 Inactive Analogues 0.95 86.84 91.48 
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DISCUSSION 
The present investigation demonstrated that HBEGF transiently activates the 
MAPK14, JNK and ERK MAPK pathways, as well as the PIK3/AKT pathway, 
downstream of the ERBB/HER tyrosine kinases in human cytotrophoblast cells.  Only 
the MAPK14 pathway appeared to be utilized to prevent apoptosis induced by O2 
fluctuations. However, it functioned in combination with the ERK, JNK, and PIK3 
pathways to induce trophoblast extravillous differentiation. HBEGF signaling is required 
to increase HBEGF protein levels when O2 is decreased to 2% (Armant et al., 2006), 
and both immunohistochemical and ELISA data indicated that HBEGF upregulation can 
be mediated by any one of the three MAPK pathways.  These data confirm prior reports 
that HBEGF inhibits apoptosis (Armant et al., 2006; Imudia et al., 2008; Leach et al., 
2008a; Wolff et al., 2007) and promotes differentiation of trophoblast cells towards a 
migratory, extravillous phenotype (Leach et al., 2004b; Lim et al., 2006; Wang et al., 
2000).  Moreover, the new findings identify separate downstream signaling pathways 
mediated by HBEGF-induced ERBB/HER activation that are responsible for each 
functional outcome. 
Although HBEGF utilizes different pathways to mediate its diverse effects in 
trophoblasts, much remains to be learned about the downstream effectors that are 
involved.  Several factors, in addition to HBEGF, that induce trophoblast migration 
include the ubiquitin-type plasminogen activator (uPA)/uPA receptor (uPAR) system, 
insulin-like growth factor (IGF), IGF-binding protein 1 (IGFBP1), hepatocyte growth 
factor (HGF) and endothelin 1 (Lala and Chakraborty, 2003). The uPA/uPAR system 
induces migration in two ways. It activates matrix metalloproteinases to initiate 
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extracellular matrix degradation, and induces intracellular Ca2+ signaling to activate 
phospholipase C (PLC), PIK3, and ERK (Liu et al., 2003).  Metalloproteinases are 
necessary for the shedding and secretion of HBEGF (Holbro and Hynes, 2004a), which 
activated PIK3 and ERK in HTR-8SVneo cells, and can induce intracellular Ca2+ 
signaling (Jessmon and Armant, unpublished observation). IGF signaling also utilizes 
ERK to induce trophoblast migration, acting through the IGF type 2 receptor (McKinnon 
et al., 2001). IGFBP1 induces migration by binding the ITGA5/ITGB1 integrin, which 
leads to activation of focal adhesion kinase and ERK (Gleeson et al., 2001). HBEGF 
also affects integrin signaling, but through integrin switching rather than direct ligation 
(Leach et al., 2004b).  TNF-alpha (TNFA) also can induce integrin switching, with 
upregulation of ITGA1 and downregulation of ITGA6 (Fukushima et al., 2003), as well 
as increased expression of vascular integrins (ITGAV and ITGB3) in an immortalized 
trophoblast cell line, TCL1 (Fukushima et al., 2005).  Endothelin 1 activates two 
pathways: one involving PLC and intracellular Ca2+ signaling, and the other involving 
ERK (Chakraborty et al., 2003).  EGF also increases migratory activity in both HTR-
8/SVneo cells (Leach et al., 2004b; Qiu et al., 2004a; Qiu et al., 2004b) and freshly 
isolated first trimester human cytotrophoblasts (Bass et al., 1994a) through the 
coordinated activation of PIK3/AKT and ERK pathways (Qiu et al., 2004b). Signaling 
through the PIK3/AKT pathway requires p70S6K and MTOR activation, but only 
increases migration if the ERK pathway is simultaneously activated (Qiu et al., 2004b).  
It remains to be ascertained whether EGF and HBEGF operate through the same 
intracellular signaling pathways in first trimester cytotrophoblast cells. In the human 
extravillous cytotrophoblast cell line, SGHPL-4, EGF stimulates cell motility through the 
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PIK3/AKT, MAPK14, and ERK pathways (LaMarca et al., 2008). Interestingly, blocking 
the MAPK14 pathway with SB203580 also inhibited activation of AKT, suggesting that 
the pathways crosstalk (LaMarca et al., 2008). In contrast to EGF, the present study 
found that the PIK3, MAPK14, ERK, and JNK pathways mediated HBEGF induction of 
trophoblast migration without cross-talk. Useful insights would be gained by identifying 
potential downstream effectors common to these four pathways. 
Several intermediates have been implicated in the regulation of trophoblast 
apoptosis.  In contrast to our finding that MAPK14 mediates the cytoprotective activity of 
HBEGF, it has been reported that H/R induces apoptosis through MAPK14 activation of 
the JNK pathway in trophoblasts from term villous explants (Cindrova-Davies et al., 
2007).  It was recently discovered that H/R activates ASK1, leading to activation of both 
MAPK14 and JNK (Cindrova-Davies, 2009).  This supports the notion that first and third 
trimester trophoblast cells engage different signaling mechanisms in response to 
oxidative stress.  In another study, JNK was responsible for inducing apoptosis in 
human first trimester placental trophoblasts exposed to hyperosmolar stress (Zhong et 
al., 2007).  In agreement, we have observed activation of JNK by H/R in the same cell 
line. 
Currently, only a few anti-apoptotic factors are known in trophoblasts.  When 
exposed to reactive O2 species (H2O2), BeWo cells undergo apoptosis, concomitant 
with an increase in the tumor suppressor gene, TP53, and a decrease in its inhibitor, 
MDM2 (Heazell et al., 2009). Interestingly, MDM2 is expressed in trophoblasts 
throughout early gestation, but disappears from cytotrophoblast cells by the third 
trimester (Fulop et al., 1998; Heazell and Crocker, 2008). Cytotrophoblast cells also 
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express nuclear TP53 more strongly in the first trimester than at term (Marzusch et al., 
1995; Roncalli et al., 1994). Taken together, it is likely that MDM2 suppresses the pro-
apoptotic influence of TP53 in first trimester trophoblasts, while TP53 becomes 
prominent late in gestation.  Indeed, trophoblast apoptosis is relatively low in the first 
trimester, even in the face of oxidative stress, but increases towards term as trophoblast 
cells become less tolerant to changes in O2 (Imudia et al., 2008; Smith et al., 2002). 
Therefore, MDM2 is a potential intermediate in the anti-apoptotic pathway downstream 
of MAPK14 signaling. 
In addition to the EGF signaling system component HBEGF, EGF is 
cytoprotective for trophoblasts.  It can inhibit apoptosis in term placental explants (Moll 
et al., 2007) and isolated term cytotrophoblasts (Smith et al., 2002) through the 
PIK3/AKT pathway (Moll et al., 2007). Studies suggest that EGF does not utilize BCL2 
to block cytokine-induced apoptosis in term cytotrophoblasts (Ho et al., 1999), but may 
work by decreasing the amount of ceramide produced during a pro-apoptotic signaling 
event (Payne et al., 1999). EGF can activate PIK3 ERK, JNK, and sphingosine kinase 1 
(SPHK1) in these cells, all of which are required subsequently to inhibit apoptosis 
(Johnstone et al., 2005; Mackova et al., 2003). Interestingly, PIK3 and ERK are needed 
to block apoptosis (Mackova et al., 2003), and the activation of SPHK1 is partially 
downstream of PIK3 (Johnstone et al., 2005).  EGF does activate MAPK14, but, in 
contrast to our findings, this pathway is not involved in the cytoprotective effects of EGF 
or the apoptotic pathway induced by cytokines (Johnstone et al., 2005).  This could 
indicate a difference between pathways activated by EGF and HBEGF, but more likely 
reflects another difference between term and first trimester trophoblasts. However, EGF 
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increases proliferation of cytotrophoblasts in term villous explants, as assessed by 
MKI67 immunostaining (Moll et al., 2007), while HBEGF is a weak mitogen for first 
trimester cytotrophoblasts (Leach et al., 2004b) and term trophoblast cells (Imudia et al., 
2008).  Although EGF is cytoprotective, it is not upregulated with HBEGF in first 
trimester trophoblast cells in response to low O2 and is, thus, less likely to be part of a 
cytoprotective mechanism during early gestation (Armant et al., 2006). 
Previous work demonstrated that the upregulation of HBEGF in first trimester 
cytotrophoblast cells cultured at low O2 is unique among the EGF ligand family (Armant 
et al., 2006).  It should be noted that this increase in protein is not accompanied by any 
change in its mRNA, indicating that HBEGF is post-transcriptionally regulated by O2.  
The upregulation of HBEGF protein during low O2 is downstream of ERBB/HER tyrosine 
kinase signaling and metalloproteolytic shedding of HBEGF from the cell surface, 
suggesting that newly secreted HBEGF activates its own translation through autocrine 
signaling.  The present study confirmed that the HBEGF-specific antagonist CRM197 
blocks upregulation of HBEGF and further indicated that this positive feedback loop can 
utilize any one of the three major MAPK pathways, but not PIK3.  While this is the first 
report that HBEGF is post-transcriptionally regulated through MAPK signaling during 
low O2, other gene products are similarly regulated downstream of MAPK.  For 
example, MAPK14 enhances translation of interleukin-8 in airway epithelial cells 
(Berube et al., 2009), activates translation of TNF in Kupffer cells and macrophages 
(Wang et al., 2009b; Yun et al., 2009), and stabilizes mRNA for interleukin 6 (Zhao et 
al., 2008) and CCAAT enhancer binding protein-δ (Li et al., 2008).  The JNK pathway is 
involved in the post-transcriptional regulation of TNF (Wang et al., 2009a) and 
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angiopoietin 2 (Phelps et al., 2006).  The ERK and PIK3 pathways are both involved in 
translation of the Na+/K+ exchanger 1 (Chiang et al., 2008) in cervical cancer cells and 
cyclooxygenase 2 in ovarian cancer cells (Cao et al., 2007).  In addition, microRNA 
(miRNA) is well known to regulate the translation and stability of mRNA in a gene-
specific fashion (Valencia-Sanchez et al., 2006), and has been shown to vary in HTR-
8/SVneo cells in response to changing O2 concentration (Donker et al., 2007).  The 
potential role of miRNA in the translational regulation of HBEGF by O2 warrants future 
exploration.  
This investigation has identified several intracellular signaling pathways activated 
by HBEGF in first trimester trophoblast cells and has linked them to its numerous 
physiological effects.  Different pathways are utilized by HBEGF to induce extravillous 
trophoblast differentiation, block apoptosis, and autoregulate HBEGF protein levels.  
This information provides a foundation for delineating the intracellular circuitry and 
transcriptional activity linking HBEGF signaling through its cognate receptors to 
physiological outcomes necessary for trophoblast function during implantation and 
placentation in humans. 
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CHAPTER 3. Post-Transcriptional Regulation of Integrin Switching by Growth 
Factor Signaling in Human Extravillous Trophoblast Cells 
SUMMARY 
As human cytotrophoblast (CTB) cells initiate extravillous differentiation, 
expression of invasion promoting integrins (e.g., ITGA1/ITGB1) increases and 
attachment-associated integrins (e.g., ITGA6/ITGB4) decreases.  HBEGF is expressed 
in CTB cells and induces “integrin-switching” in vitro to the same extent as culture on 
Matrigel (MG) basement membrane.  The human first trimester CTB cell line HTR-
8/SVneo was cultured serum-free for 24 h on fibronectin or on MG to examine 
downstream mechanisms that regulate integrin expression.  ITGA1 and ITGA6 
visualized by immunofluorescence or immunoperoxidase labeling were altered as 
expected by culture on MG or with HBEGF, which was confirmed by quantitative image 
analysis.  Inhibiting HBEGF signaling with a specific antagonist, CRM197, or with a pan-
ERBB kinase inhibitor blocked integrin switching induced by HBEGF, but not by MG.  
Furthermore, CTB invasion and integrin switching failed on growth factor-reduced MG. 
Integrin switching, but not invasion, could be restored specifically with recombinant 
HBEGF.  Inhibitors of MEK1/2 (U0126), PI3 kinase (LY294002), p38 (SB203580), and 
JNK (SP600125) were each able to specifically block integrin-switching induced by 
HBEGF. Integrin switching induced by treatment with HBEGF or culture on MG did not 
alter ITGA1 or ITGA6 mRNA expression, as quantified by real time PCR, indicating 
post-transcriptional regulation. In conclusion, HBEGF is sufficient to induce integrin-
switching, although other factors in MG appear to have similar activity.  The same 
downstream pathways necessary for HBEGF induction of integrin switching were 
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previously found to be required for HBEGF-induced CTB migration, supporting the view 
that integrin switching is a key inaugural step in invasive differentiation. 
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INTRODUCTION 
Embryo implantation in the uterine endometrium is mediated by trophoblast cells 
located on the surface of the blastocyst that, after invasion of the uterus, give rise to the 
placenta (Armant, 2005).  This process requires trophoblast differentiation from an 
epithelial phenotype to an invasive phenotype (Knofler, 2010).  Trophoblast invasion of 
the decidualized maternal stroma is both interstitial and intravascular, which results in 
the remodeling of the uterine spiral arteries to increase blood flow into the intervillous 
space of the developing placenta (Pijnenborg et al., 1983b). Alterations in the 
endometrial luminal epithelium, and signaling by hormones, cytokines, and growth 
factors are all associated with successful implantation (Norwitz et al., 2001).  Paracrine 
and autocrine signaling drives developmental progression of the endometrium, as well 
as the differentiation of trophoblast cells. Trophoblast cells expressing divergent 
phenotypes are observed in close proximity during early development in vivo, 
suggesting that differentiation can occur rapidly under the direction of extrinsic cues in 
the microenvironment (Armant, 2005). This developmental plasticity suggests the 
hypothesis that the trophoblast utilizes signaling mechanisms that translate local cues 
into functional changes with high efficiency and speed. 
Cytotrophoblast (CTB) stem cells of the placenta are a polarized epithelium 
attached to a basement membrane that strongly express E-cadherin and integrin α6β4 
(ITGA6/ITGB4) (Damsky et al., 1992).  Individual CTB cells proliferating within the 
anchoring villi differentiate to invasive extravillous trophoblast (EVT) cells that leave the 
cell column and invade the uterine decidua.  As they do this, expression of 
ITGA6/ITGB4 diminishes and ITGA1/ITGB1 intensifies in a process termed “integrin 
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switching” (Damsky et al., 1994).  Although the complete mechanism that regulates 
integrin switching in vivo is unknown, factors that induce trophoblast motility might 
initiate EVT differentiation through integrin switching. CTB cells undergo integrin 
switching while invading the decidua, suggesting that matrix components secreted by 
decidual fibroblasts are important mediators of this event (Damsky et al., 1992).  
Integrin switching can also be induced when CTB cells isolated from first trimester 
placentas are cultured on Matrigel (MG), a tumor-derived basement membrane 
(Damsky et al., 1994). An immortalized human first trimester CTB cell line, HTR-
8/SVneo, similarly demonstrates integrin switching when cultured on MG (Kilburn et al., 
2000b). When cultured on individual extracellular matrix components that are incapable 
of inducing integrin switching, integrin switching is restored in this cell line after 
treatment with EGF-like growth factors, including EGF, TGFA and HBEGF (Leach et al., 
2004a).   
HBEGF appears to act as a primary initiating factor in normal implantation.  It is 
upregulated during the window of implantation in both mice (Das et al., 1994c) and 
humans (Leach et al., 1999b), and is specifically expressed juxtaposed to the 
implantation site in mice (Das et al., 1994c) and surrounding an implanted blastocyst in 
hamsters (Wang et al., 2002).  In addition, intraluminal injection of HBEGF induces 
implantation of rat embryos in a delayed implantation model (Tamada et al., 1999).  
HBEGF expression is altered in the endometrium of women with unexplained fertility 
(Aghajanova et al., 2008) and conditional deletion of HBEGF in the mouse uterus will 
delay implantation of blastocysts without changing the preimplantation ovarian estrogen 
secretion (Xie et al., 2007).  There is evidence that HBEGF is capable of stimulating 
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trophoblast invasion.  Exogenous HBEGF accelerates blastocyst hatching from the 
zona pellucida and outgrowth of the trophectoderm on fibronectin (Wang et al., 2000).  
HBEGF also increases blastocyst adhesion competency and trophoblast outgrowth in 
hamsters (Mishra and Seshagiri, 2000; Seshagiri et al., 2002).  HBEGF induces 
trophoblast invasion from first trimester chorionic villi explants cultured on Matrigel 
(Leach et al., 2004a) and stimulates motility in an immortalized first trimester trophoblast 
cell line (Jessmon et al., 2010).  However, the molecular regulation of integrin switching 
by either MG or growth factors remains to be established. 
Integrin switching in trophoblast cells could be a key mechanism regulating 
normal implantation, and might also provide insights into pathologies stemming from 
inadequate trophoblast invasion, such as preeclampsia (PE).  Integrin switching is 
highly restricted in placentas of women with PE, where expression of ITGA6 and other 
proteins associated with non-motile trophoblast persist (Zhou et al., 1993; Zhou et al., 
1997a).  Therefore, the shallow EVT invasion characteristic of PE could derive from this 
failure.  Interestingly, HBEGF expression is greatly reduced in placentas of women with 
PE (Leach et al., 2002a), suggesting an association with the lack of integrin switching in 
PE, and a role in regulating integrin switching in healthy placentas. 
The HTR-8/SVneo CTB cell line was used to evaluate integrin switching induced 
by MG or growth factors in vitro, examining extrinsic factors that could be responsible 
for integrin switching during implantation and early events of placentation. Since both 
MG and HBEGF induce integrin switching, it can be hypothesized that HBEGF and MG 
promote EVT differentiation through a common mechanism, perhaps due to presence of 
HBEGF bound to MG.  Furthermore, it is important to identify the intracellular signaling 
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pathways that HBEGF utilizes to induce integrin switching in CTB cells. Previously, we 
found that signaling pathways downstream of HBEGF required to stimulate CTB motility 
include phosphoinositide-3-kinase (PIK3) and the three MAPK pathways mediated by 
mitogen-activated protein kinase 1/3 (MAPK1; ERK1/3), MAPK14 (p38) and c-Jun N-
terminal kinase 1 (MAPK8/JNK) (Jessmon et al., 2010). Additionally, the role of 
transcription in regulating integrin switching was examined, since previous 
investigations have focused strictly on integrin protein levels and not reported whether 
the corresponding mRNAs were altered. 
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MATERIALS & METHODS 
Cell Culture and Treatments 
The first trimester human CTB cell line HTR-8/SVneo (Graham et al., 1993b) 
(provided by Dr. Charles Graham of Queens University) was cultured serum-free for 24 
h on fibronectin- or MG-coated plastic, or on a gel formed by MG (BD Biosciences). 
Fibronectin was used to precoat plastic as previously described (Kilburn et al., 2000b). 
Plastic was coated with MG (Leach et al., 2004a; Liu et al., 2004) by diluting MG 1:5 in 
cold serum-free media, incubating in a culture flask for 1 h at 37°C, and washing 
residual MG away.  Precoating with MG reduced background stain relative to cells 
cultured on a gel after subsequent immunocytochemical labeling of cells.  MG was used 
to form gels by adding ice-cold, undiluted MG and incubating for 1 h at 37°C.  The same 
procedures were followed for MG that had been depleted of its growth factors,  (growth 
factor-reduced MG; GFR-MG; BD Biosciences).  Recombinant HBEGF (R&D Systems), 
specific inhibitors of MEK1/2 (U0126), PIK3 (LY294002), p38 (SB203580), JNK 
(SP600125), and their corresponding inactive structural analogues (U0126, LY303511, 
SB202474, and JNK Inhibitor II negative control, respectively) were purchased from 
Calbiochem and were added during cell culture, as described by Jessmon et al. 
(Jessmon et al., 2010).  
Western Blotting 
Western blots were performed, as previously described (Kilburn et al., 2000b).  
Briefly, cellular lysates were diluted in SDS sample buffer containing 5% β-
mercaptoethanol, run on precast 4%–20% Tris-HCl gradient gels (BioRad), and blotted 
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with primary antibodies.  Antibodies against ITGA1 (Upstate Biotechnology Inc.) and 
ITGA6 (Chemicon International) were diluted 1:1000 in Tris-Tween Buffered Saline 
(TTBS) containing 5% milk.  Secondary anti-rabbit and anti-mouse antibodies (Cell 
Signaling Technologies) were detected by enhanced chemiluminescence (Amersham 
Pharmacia Biotech).  Bands were observed for ITGA1 and ITGA6 at 130-150 kDa and 
120 kDa, respectively. 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton-X100, 
and stained for the presence of HBEGF protein, as previously described (Kilburn et al., 
2000b; Leach et al., 2004a).  ITGA1 and ITGA6 were visualized by 
immunocytochemistry using secondary antibodies conjugated to fluorescein and 
epifluorescence microscopy or a peroxidase-conjugated anti-mouse/anti-rabbit kit (Dako 
EnVision System-HRP), as described by Armant et al. (Armant et al., 2006).  Image 
analysis was performed with an Orca (Hamamatsu) digital camera and quantified 
(peroxidase label only) according to published procedures (Leach et al., 2002a). 
ELISA 
ELISA was conducted using the HBEGF DuoSet ELISA Development kit (R&D 
Systems), as previously described (Armant et al., 2006; Leach et al., 2008b). The 
optical density of the final reaction product was determined at 450 nm using a 
programmable multiplate spectrophotometer (Power Wave Workstation; Bio-Tek 
Instruments) with automatic wavelength correction. 
qPCR 
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ITGA1 and ITGA6 mRNAs were examined by endpoint and semi-quantitative real 
time RT-PCR and normalized to succinate dehydrogenase mRNA.  According to the 
newly recommended MIQE guidelines, semi-quantitative real time RT-PCR will be 
referred to as qPCR (Bustin et al., 2009).  RNA from HTR-8/SVneo cells was collected 
using the miRNeasy kit from Qiagen according to the manufacturer’s protocol.  RNA 
concentration was determined using a NanoDrop spectrophotometer and purity was 
ascertained with an Agilent Bioanalyzer.  Reverse transcription was performed using the 
Quantitect Reverse Transcription kit (Qiagen) and endpoint PCR was conducted using 
the HotStarTaq Master Mix Kit (Qiagen) according to the manufacturer’s instructions.  
Thermal cycling for qPCR was conducted using the Quantitect SYBR Green PCR kit 
without UNG in a final volume of 25 µL on an Applied Biosystems 7500 Fast real time 
thermal cycler.  An appropriate housekeeping gene was chosen from a panel of genes:  
RRN18S, ACTB, GAPDH, RPL13A, RPLP0, and SDHA.  SDHA (succinate 
dehydrogenase) had the least variability among all treatments.  Semi-quantiative 
analysis was performed according to the ΔΔCt method (Pfaffl, 2001).  Pre-validated 
primers for the housekeeping genes, ITGA1 and ITGA6 were obtained from Qiagen. 
Statistics 
All assays were performed in triplicate, and all experiments were repeated at 
least three times and are reported as mean ± SEM.  Statistical significance was 
determined at P < 0.05 by ANOVA with the Student-Newman-Keuls post hoc test, using 
SPSS version 12.0 statistics software (SPSS, Chicago, IL). 
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RESULTS 
Integrin Switching Induced by MG and HBEGF 
HTR-8/SVneo CTB cells were cultured on a MG gel or on fibronectin-coated 
plates with 1 nM HBEGF.  Western blotting demonstrated that, as compared to controls 
(fibronectin-coated plates without HBEGF), culturing CTB cells in the presence of 
HBEGF or on MG upregulated ITGA1 and downregulated ITGA6 (Fig. 3.1 A).  The 
same antibodies used for immunofluorescence microscopy demonstrated that treatment 
with HBEGF caused ITGA1 to localize within structures that appeared to be focal 
adhesions (Fig. 3.1 E compared to D), while ITGA6 disappeared from these structures 
(Fig. 3.1 C compared to B).  Immunocytochemistry and quantitative image analysis (Fig. 
3.1 F-K) established an equivalent effect of HBEGF supplementation (Fig. 3.1 H, I) or 
MG precoating (Fig. 3.1 J, K) on integrin switching as compared to culture on fibronectin 
alone (Fig. 3.1 F, G). 
Integrin Switching Induced by MG is not Dependent upon HBEGF Signaling 
Since both HBEGF and MG could induce integrin switching, it is possible that 
HBEGF associated with the matrix could be responsible for the effects of MG.  
Therefore, the inhibition of HBEGF signaling during CTB culture on MG would be 
expected to prevent integrin switching.  Previous investigation has demonstrated that 
HBEGF binds to ERBB1 or ERBB4 to activate downstream pathways (Armant et al., 
2006).  The abilities of a specific antagonist of HBEGF (CRM197) or a pan-ERBB 
kinase inhibitor (Ornskov et al., 2006) to block the effects of HBEGF on integrin 
switching were first examined.  Both inhibitors were able to prevent integrin switching in  
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CTB cells cultured on fibronectin in the presence of 1 nM HBEGF for 24 h (Fig. 3.2 A).  
However, when cells were cultured on a MG precoat in the presence of either inhibitor 
for 48 h, integrin switching was not abrogated (Fig. 3.2 B).  In addition, HBEGF protein 
was not detectable by ELISA in solubilized MG (data not shown).  These findings 
indicate that HBEGF and MG induce integrin switching independently, and that other 
components in MG are capable of inducing integrin switching. 
HBEGF Restores Integrin Switching On Growth Factor-reduced MG 
Although HBEGF does not appear to be responsible for the ability of MG to 
induce integrin switching, it is possible that other growth factors or matrix components of 
MG have that capacity.  To examine the role of growth factors in MG, we first assessed 
invasion of CTB cells on gels composed of either MG or GFR-MG.  Phase contrast light 
microscopy demonstrated that CTB cells failed to invade GFR- MG, whereas cells 
formed into invading streams on complete MG and penetrated deep into the gel (Fig. 
3.3 A-C).  Culture on GFR-MG in the presence of 10 nM HBEGF for 48 h was 
insufficient to rescue the invasive phenotype (Fig. 3.3 D), suggesting that while integrin 
switching is associated with invasion (Zhou et al., 1997b), other steps are required that 
cannot be restored by HBEGF signaling.  Although there was no apparent change in 
cell invasion, we examined the potential of HBEGF and other growth factors thought to 
influence EVT differentiation (Knofler, 2010) to induce integrin switching on a GFR-MG 
precoat.  After 48 h, immunocytochemistry and quantitative image analysis 
demonstrated that integrin switching occurred on MG, but not on GFR-MG, could be 
fully restored on GFR-MG by supplementation with 1 nM recombinant HBEGF, and was 
partially restored with EGF, TGFA, AREG, and VEGF (Fig. 3.4).  More specifically, EGF  
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could increase the expression of ITGA1 compared to GFR-MG, but was unable to 
suppress production of ITGA6. Conversely, TGFA, AREG, and VEGF were able to 
decrease expression of ITGA6 compared to GFR-MG, but were unable to significantly 
upregulate ITGA1.  BTC, another EGF-related growth factor, did not alter integrin 
expression. Surprisingly, IGF2 and LIF, previously found to promote trophoblast motility 
or invasion (Burton et al., 2007; Hamilton et al., 1998), had no effect on expression of 
ITGA1 or ITGA6. 
HBEGF Induces Integrin Switching Through Multiple Signaling Pathways 
As HBEGF appears unique in its ability to fully induce integrin switching on GFR-
MG, downstream intracellular signaling pathways utilized by HBEGF were examined.  
We previously reported that HBEGF induces CTB cell migration through the MEK1/2, 
PIK3, p38, and JNK pathways (Jessmon et al., 2010).  Using inhibitors of each of these 
pathways, their involvement in HBEGF-induced integrin switching was examined.  
Inhibitors of MEK1/2 (U0126), PIK3 (LY294002), p38 (SB203580), and JNK (SP600125) 
were each able to block integrin switching induced by HBEGF, while less active 
structural analogues of each inhibitor were without effect (Fig. 3.5).  These data indicate 
that HBEGF requires all four pathways to induce integrin switching. 
Post-Transcriptional Regulation of Integrin Switching  
To examine the effects of HBEGF and MG on integrin mRNA expression, RNA 
collected from CTB cells was reverse transcribed and both endpoint and qPCR were 
performed.  As demonstrated by agarose gel electrophoresis after endpoint PCR, 
treatment with HBEGF or culture on MG did not appear to alter ITGA1 or ITGA6 mRNA  
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expression (Fig. 3.6 A).  Measurement of ITGA1 and ITGA6 transcripts by qPCR, 
normalized to SDHA expression, confirmed the absence of a change in the 
concentration of either mRNA due to either treatment (Fig. 3.6 B), suggesting that the 
proteins are regulated post-transcriptionally during integrin switching.  
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DISCUSSION 
CTB cells adhere to the maternal uterine endometrium and invade the underlying 
stromal tissue to establish a placenta.  Integrin switching appears to fulfill an important 
role in the initiation of extravillous differentiation.  Integrin ITGA6/ITGB4 is characteristic 
of non-motile CTB cells, while ITGA1/ITGB1 promotes invasion (Damsky et al., 1994), 
representative of several identified molecular modifications associated with EVT 
differentiation (19).  Many cytokines, growth factors and hormones can regulate this 
change in protein expression (Knofler, 2010).  Both HBEGF and MG induced integrin 
switching in an immortalized CTB cell line, and although the MG mechanism did not rely 
on HBEGF or ERBB signaling, both MG and HBEGF regulated expression through a 
post-transcriptional mechanism. It can be contemplated that CTB cells retain transcripts 
that are translated only when instructed by extrinsic cues encountered during 
development, which direct their differentiation and adaptation to local changes in the 
microenvironment. Therefore, specific proteins could be accumulated rapidly without the 
inefficiencies associated with transcription and its layers of regulation. Several 
mechanisms to repress or activate specific transcripts are known that involve 
ribonucleoprotein complexes and small inhibitory RNA or micro-RNA species (Filipowicz 
et al., 2008; Jopling et al., 2005; Orom et al., 2008; Pillai et al., 2007; Vasudevan and 
Steitz, 2007; Vasudevan et al., 2007). 
The effects of MG were not dependent on HBEGF signaling or other growth 
factors of the EGF signaling system that utilize ERBB receptor tyrosine kinases, 
indicating that other growth factors associated with MG might induce extravillous 
differentiation of CTB cells.  We were unable to detect HBEGF in MG by western 
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blotting or ELISA (data not shown); however, the effective activity of HBEGF (~1 nM) 
would be below detection limits.  MG is a biologically active, basement membrane-like 
matrix secreted by the Engelbreth-Holm Swarm (EHS) tumor that is widely used in cell 
culture, cell differentiation and invasion assays (Biederer and Scheiffele, 2007; 
Kleinman and Martin, 2005; Terranova et al., 1986).  CTB cells cultured on MG 
demonstrated integrin switching, but not when growth factors were removed.  A 
previous analysis of growth factors known to be important in bone cell proliferation and 
differentiation determined that TGFB, EGF, IGF1, bFGF, and PDGF were present in MG 
(Vukicevic et al., 1992).  The integrin switching observed on MG is also observed when 
first trimester CTB cells are cultured on a collagen IV/laminin matrix (Damsky et al., 
1994).  Disruption of interactions with laminin or collagen IV inhibits CTB invasion, 
which suggests that matrix components signal through adhesion molecules such as 
integrins to induce cellular invasion.  This idea was not supported by the finding that 
matrix components of MG lacked the capacity to induce integrin switching.  It is likely 
that signaling from both matrix components and growth factors can contribute to integrin 
switching.  Indeed, CTBs grown on MG secrete PlGF and cells grown on laminin 
secrete both PlGF and VEGF-A, suggesting that these growth factors influence integrin 
switching (Zhou et al., 1997b; Zhou et al., 2002).  Disruption of ligand binding to either 
VEGFR-1 or VEGFR-3 of CTBs cultured in vitro results in decreased ITGA1 expression, 
suggesting that VEGF signaling helps to mediate integrin switching.  Our results 
suggest that VEGF, in combination with other signaling factors, may influence integrin 
switching in CTBs.  It could be speculated that growth factors induce changes in CTB 
cells that allow matrix components to subsequently initiate integrin outside-in signaling 
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that induces invasion (Aplin et al., 1998; Armant, 2005; Burridge and Chrzanowska-
Wodnicka, 1996; Giancotti, 2000; Hynes, 1992). 
These are the first data to demonstrate that HBEGF regulates trophoblast 
invasion at the post-transcriptional level.  A previous study that examined freshly 
isolated first and second trimester CTB cells detected an increase in ITGA1 mRNA after 
culturing on MG for 24 hr (Damsky et al., 1994).  It is important to note that cells were 
compared that were attached either to fibronectin (with or without HBEGF) or MG, while 
the previous study compared cells attached to MG with unattached, freshly isolated 
CTB cells.  Therefore, differences in the findings could be due to cell attachment.  
Further analysis is required to delineate how HBEGF upregulates integrin protein post-
transcriptionally.  One possibility is that ITGA1 mRNA is sequestered and translationally 
repressed.  A change in microenvironment that initates HBEGF signaling or other 
mechanisms that activate the appropriate downstream pathways could then derepress 
translation of the transcript.  MicroRNAs (miRNAs) are widely studied for their role in 
translational repression.  MiRNAs are ~22 nt endogenous small RNA species that target 
mRNA transcripts within complementary 3’UTR sequences to repress or activate 
translation (Kim and Nam, 2006; Pillai et al., 2007).  A stable pool of ITGA1 transcripts 
could be bound by miRNA and hence translationally repressed until derepressed by 
HBEGF signaling.  HBEGF could simultaneously elevate expression of specific miRNAs 
that bind ITGA6 mRNA to inhibit its translation.  Through this mechanism, CTB cells 
would rapidly regulate integrins for invasion through extracellular matrices during 
embryo implantation without expending energy for transcription.  Indeed, rapid 
mechanisms could be in place that allow CTB cells on the surface of a blastocyst to 
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adhere to the uterine epithelial surface and then invade the underlying basement 
membrane and decidual stroma.  Changes in matrix components would be encountered 
with different integrin expression profiles.  As the placenta forms, trophoblast cells in 
floating villi express predominantly ITGA4, CTB cells invading the decidua favor ITGA1 
over ITGA6, and CTB cells that invade maternal blood vessels upregulate ITGAV, 
demonstrating that trophoblasts adapt to different extracellular matrix environments 
(Zhou et al., 1997b).  Therefore, it is feasible that other rapid cellular responses are 
responsible for integrin-switching in trophoblasts during implantation. 
Previously, a role in HBEGF-induced cell migration was established for the p38, 
ERK1/2 (p42/44), PIK3 and JNK pathways (Jessmon et al., 2010).  These same 
downstream pathways were necessary for induction of integrin switching, supporting the 
view that integrin switching is a key inaugural step in EVT differentiation.  It is likely that 
this switch is involved in HBEGF-induced cell migration.  EGF can also induce 
trophoblast cell motility via similar downstream pathways.  In SGHPL-4 cells, EGF 
stimulated motility through PIK3, p38 and ERK1/2 (p42/44) (LaMarca et al., 2008).  In 
addition, EGF, as found in decidua conditioned media, promotes trophoblast migration, 
but through downregulation of the gap junction protein Cx40 in JAR cells (Oh et al., 
1993; Wright et al., 2006).  Integrin-mediated cell attachment likely initiates kinase 
signaling, either through constitutive localization of FAK to the integrin α subunit, or 
growth factor-mediated recruitment of FAK to the integrin β subunit (Giancotti, 2000).  It 
is possible that integrin attachment-mediated signaling integrates with HBEGF to 
regulate integrin switching. 
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CHAPTER 4.  MMP2 Controls Low Oxygen-Induced Autocrine HBEGF Signaling in 
Human First Trimester Trophoblast Cells 
SUMMARY 
Heparin-binding EGF-like growth factor (HBEGF) is expressed by trophoblast 
cells throughout gestation, but is absent in placentas from women with preeclampsia.  
HBEGF is upregulated at low O2 concentrations through a mechanism that requires 
metalloproteinase-mediated shedding of its extracellular domain.  Signaling downstream 
of HBEGF receptors (ERBB1 and ERBB4) both increases HBEGF synthesis and 
prevents apoptosis caused by low O2. Transcriptional events and metalloproteinases 
involved in the upregulation of HBEGF protein were examined using a human first-
trimester cytotrophoblast cell line, HTR-8/SVneo, exposed to 20% O2, 2% O2 or 250 µM 
CoCl2 that upregulates hypoxia inducible factor (HIF) at 20% O2.  HBEGF protein, 
quantified by ELISA, increased in cells cultured at 2% O2 for 6 h or in the presence of 
CoCl2 for 2 h.  The RNA polymerase II inhibitor, α-amanitin, inhibited HBEGF protein 
accumulation during either treatment, suggesting that factors regulating HBEGF 
upregulation require hypoxia-stimulated transcription.  The accumulation of HIF1α and 
HIF2α at 2% O2 or during CoCl2 treatment was confirmed by western blotting.  
Microarray analysis of the transcriptome demonstrated that after 4 h at 2% O2 
expression of genes related to metalloproteinase function increased, including BSG, 
MMP-2 and MMP-15.  Inhibitors specific for MMP2 or both MMP2 and MMP9, but not 
MMP9 alone, prevented the increase in HBEGF at 2% O2.  These findings indicate that 
the increased expression of HBEGF at 2% O2 is dependent upon HIF and de novo 
transcription.  Of several early response genes, experimental evidence implicates MMP-
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2 as a critical member of a proteolytic cascade that mediates the shedding of HBEGF to 
initiate autocrine signaling required for its rapid synthesis. 
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INTRODUCTION 
A low O2 environment is present at the human implantation site and persists for 
the first 10 weeks of pregnancy as invasive cytotrophoblast (CTB) cells penetrate the 
maternal decidua (Burton and Jauniaux, 2004; Burton et al., 1999; Jauniaux et al., 
2001a; Rodesch et al., 1992).  Whereas most cells do not survive well at low O2 
concentrations, trophoblast cells actually proliferate faster at 2% O2 than at atmospheric 
levels (20%) (Genbacev et al., 1996b; Genbacev et al., 1997b).  After 10 weeks of 
gestation, trophoblast plugs in the uterine spiral arteries are dislodged and maternal 
blood flows freely into the intervillous space of the placenta, raising O2 from 
approximately 18 mm Hg to 60 mm Hg (Jauniaux et al., 2001a; Rodesch et al., 1992).  
As proliferation abates due to the rise in O2, trophoblast cells become more invasive 
(Norwitz et al., 2001).  Survival factors must be in place that protect the trophoblast from 
hypoxia, particularly during early placentation. Several proteins have been identified that 
provide survival function to protect against apoptosis in CTB (Armant et al., 2006; Dash 
et al., 2005; Jaleel et al., 2004; Mackova et al., 2003; Singh et al., 2010). 
A member of the epidermal growth factor (EGF) signaling system, heparin-
binding EGF-like growth factor (HBEGF) is present at the implantation site in mice and 
is required for normal implantation (Leach et al., 1999b; Yoo et al., 1997a). Maternal 
HBEGF deficiency in mice defers on-time implantation, leading to reduced litter size 
(Xie et al., 2007), and suggesting its important role in implantation.  HBEGF is also 
present in the human endometrium during the window of implantation (Leach et al., 
1999b; Stavreus-Evers et al., 2002; Yoo et al., 1997a).  HBEGF, but not other EGF 
family members, is upregulated in human CTB cells cultured at 2% O2 and can 
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stimulate differentiation to the invasive phenotype at higher O2 concentrations (Armant 
et al., 2006; Leach et al., 2004a). Inhibition of HBEGF signaling during CTB culture at 
low O2 results in apoptosis, identifying HBEGF as a critical survival factor in that 
environment. During the first trimester, survival and invasive differentiation are key 
functions required for expansion of the placenta and remodeling of the spiral arteries 
(Hunkapiller and Fisher, 2008; Staun-Ram and Shalev, 2005; Zhou et al., 1997b).  
Previously, it was reported that HBEGF expression is deficient in placentas from women 
with preeclampsia, which could contribute to the reduced trophoblast invasion and 
increased apoptosis characteristic of this syndrome (Leach et al., 2002a).   
HBEGF is synthesized intracellularly as transmembrane proHBEGF and is 
secreted through shedding from the cell membrane by proteolytic cleavage, allowing it 
to activate its cognate receptor tyrosine kinases (EGF receptor/ERBB1; ERBB4) and 
initiate intracellular signaling (Holbro and Hynes, 2004b).  HBEGF specifically binds 
ERBB1 and ERBB4, but can transactivate ERBB2 or ERBB3 due to heterodimerization 
among the four ERBB receptor family members .  Downstream of its receptors, HBEGF 
signaling induces an increase in trophoblast motility, prevents apoptosis, and 
upregulates its biosynthesis through an autocrine feedback mechanism (Armant et al., 
2006; Jessmon et al., 2010; Leach et al., 2004a). Although HBEGF is upregulated 
(~100-fold) in CTB cells after exposure to 2% O2 (Armant et al., 2006), HBEGF mRNA 
remains unchanged and abundant (2500 copies/cell) at both O2 concentrations.  
Blocking HBEGF accumulation with a metalloproteinase inhibitor leads to increased 
apoptosis at low O2 that is rescued with recombinant HBEGF, but not other EGF-like 
ligands.  Autocrine HBEGF activity in CTB cells requires, in addition to 
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metalloproteinase-mediated shedding of HBEGF, binding to either ERBB1 or ERBB4.  
Blocking HBEGF signaling also prevents its upregulation at 2% O2, suggesting that low 
levels of resident proHBEGF are cleaved through activation of metalloproteinases to 
initiate its autocrine synthesis downstream of ERBB receptors in a positive feedback 
loop. 
To further investigate the regulation of HBEGF expression by O2, we examined 
the roles of nacent transcription, O2-sensitive transcription factors and 
metalloproteinases, using an immortalized human CTB cell line. 
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MATERIALS & METHODS 
Cell Culture and Treatments 
The first trimester human CTB cell line HTR-8/SVneo (Graham et al., 1993b) was 
cultured at either 20% O2 or 2% O2, as previously described (Leach et al., 2004a; Leach 
et al., 2008b).  Cells were cultured in the presence of α-amanitin (Sigma-Aldrich), CoCl2 
(250µM; Sigma-Aldrich) or inhibitors (EDM Chemicals, Inc., Gibbstown, NJ) specific for 
MMP2 and MMP9 ((2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-
phenylpropionamide, BiPS; 100 nM), MMP2 only ((2-((isopropoxy)-(1,1′-biphenyl-4-
ylsulfonyl)-amino))-N-hydroxyacetamide; 250 nM) or MMP9 only (MMP-9 Inhibitor I; 100 
nM), prepared in sterile DMEM/F-12 media at the indicated times and concentrations.   
Western Blotting 
Western blots were performed as previously described (Kilburn et al., 2000b).  
Briefly, cellular lysates were diluted in SDS sample buffer containing 5% β-
mercaptoethanol, run on precast 4%–20% Tris-HCl gradient gels (BioRad), and blotted 
with antibodies against HIF1A (R&D Systems), HIF2A/EPAS1 (Novus Biologicals) or 
HIF3A (Novus Biologicals) diluted 1:1000 in TTBS and 5% milk.  Densitometry was 
used to quantify grey levels over protein bands of interest using image analysis software 
(SimplePCI).  Background grey levels determined in a blank lane were subtracted to 
obtain the specific grey level for each band. 
ELISA 
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ELISA was conducted using the HBEGF DuoSet ELISA Development kit (R&D 
Systems), as previously described (Armant et al., 2006; Leach et al., 2008b). The 
optical density of the final reaction product was determined at 450 nm using a 
programmable multiplate spectrophotometer (Power Wave Workstation; Bio-Tek 
Instruments) with automatic wavelength correction.  Data are presented as picograms 
(pg) of HBEGF per microgram (µg) of total protein. 
qPCR 
RNA from HTR-8/SVneo cells was collected using the miRNeasy kit (Qiagen) 
according to the manufacturer’s protocol.  RNA concentration was determined using the 
NanoDrop spectrophotometer and purity was ascertained with an Agilent Bioanalyzer 
(Agilent).  RNA was used either for microarray analysis, as described below, or in 
subsequent qPCR (Bustin et al., 2009) analysis.  Reverse transcription was performed 
using the Quantitect Reverse Transcription kit (Qiagen) and qPCR was conducted with 
the Quantitect SYBR Green PCR kit without UNG (Qiagen) in a final volume of 25 µL.  
An appropriate housekeeping gene was chosen from a panel of genes:  RRN18S, 
ACTB, GAPDH, RPL13A, RPLP0, SDHA.  For validating the microarray results, SDHA 
(succinate dehydrogenase) was chosen as an internal reference because it varied the 
least with all experimental treatments.  Semi-quantiative analysis was performed 
according to the ΔΔCt method (Pfaffl, 2001).  Primers for the housekeeping genes and 
for HBEGF were obtained from Qiagen. 
mRNA Microarray 
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The Agilent 60-mer Whole Human Genome G4112F Microarray (Agilent, Santa 
Clara, CA) having about 45,000 probes was used to obtain the global mRNA expression 
profiles (Agilent part number G4410-90040).  Total RNA was processed, labeled, and 
hybridized onto the microarrays according to the manufacturer’s protocols.  Microarray 
slides were then scanned using the Agilent scanner and microarray data extracted 
using the Agilent Feature Extraction software v.9.5.3.1.  Features altered at least 2-fold 
with good correlation between the duplicate time course patterns (Corr. Coeff > 0.7) and 
a signal above 100 were selected for further analysis. 
Statistics 
All assays were performed in triplicate, and all experiments were repeated at 
least three times and are reported as mean ± SEM.  Statistical significance was 
determined at P < 0.05 by ANOVA with post hoc students t-test, using SPSS version 
12.0 statistics software (SPSS, Chicago, IL).  Significance in the microarray analysis 
was determined at p < 0.1. 
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RESULTS 
O2 regulates HBEGF through HIF1α and HIF2α 
CoCl2, a chemical mimic of hypoxia that stabilizes HIF (Jiang et al., 1997), was 
used to examine the effect of 2% O2 on HBEGF expression in the HTR-8/SVneo CTB 
cell line.  Culturing CTB cells either for 4 h at 2% O2 or in the presence of 250 µM CoCl2 
for 30 min to 2 h stabilized the transcription factors, HIF1α and HIF2α, as indicated by 
their increased labeling on Western blots (Fig. 4.1).  HIF2α increased very rapidly during 
CoCl2 treatment, peaking at 30 min, while HIF1α took longer to accumulate. HIF3α was 
either unaffected or decreased slightly in CTB cells culture at 2% O2 or in the presence 
of CoCl2.  In addition, treatment with CoCl2 for 1 to 8 h increased both cellular and 
secreted levels of HBEGF protein (Fig. 4.2).  These findings suggest that O2 regulates 
HBEGF synthesis and secretion through its effect on the protein concentrations of 
HIF1α and HIF2α. 
New Transcription is Required to Increase HBEGF  
The involvement of HIF transcription factors in the regulation of HBEGF by O2 
suggested a mechanism based on differential gene expression. Therefore, CTB cells 
were cultured at 2% O2 with or without α-amanitin, an inhibitor of RNA polymerase-II 
(Lindell et al., 1970; Stirpe and Fiume, 1967), to examine the role of new transcription in 
the upregulation of HBEGF protein.  Elevation of HBEGF protein after culture at 2% O2 
for 6 h was abrogated in a dose-dependent manner by α-amanitin with maximal 
inhibition attained at 5 µM (Fig. 4.3).  The inhibitor also blocked the CoCl2-mediated 
increase in both cellular and secreted forms of HBEGF (Table 4.1). It was previously  
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Table 4.1.  Upregulation of HBEGF protein by CoCl2 requires new transcription.  
α-Amanitin 
(µg/mL) 
HBEGF (pg/µg) 
 Lysate  Media 
 CoCl2 (µM)  CoCl2 (µM) 
 0 250  0 250 
0 0.012 ± 0.007 76.963 ± 37.262  0.00 ± 0.00 0.721 ± 0.62 
5 0.035 ± 0.015 0.086 ± 0.051  0.001 ± 0.001 0.001 ± 0.001 
10 0.035 ± 0.016 0.043 ± 0.031  0.001 ± 0.001 0.001 ± 0.001 
HBEGF protein was quantified by ELISA in lysates and media covering CTB cells 
cultured with or without 250 µM CoCl2.  CoCl2 treatment induced an increase in both 
cellular and secreted HBEGF that was abrogated by either 5 or 10 µg/mL α-amanitin.  
Values are listed as averages ± standard error. 
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demonstrated that HBEGF synthesis and secretion increase at 2% O2 without a 
detectable change in levels of its transcript (Armant et al., 2006). Therefore, it is unlikely 
that HIF signaling directly targets HBEGF transcription. The effects of α-amanitin on 
HBEGF suggest that transcription of other genes, perhaps those regulated by HIF1α or 
HIF2α, are required to initiate HBEGF protein synthesis. 
O2 Regulates Transcription of Metalloproteinases  
It was previously shown that HBEGF autocrine signaling through ERBB receptors 
upregulates HBEGF protein levels at 2% O2 (Armant et al., 2006; Jessmon et al., 2010). 
Cell surface proHBEGF is proteolytically cleaved, releasing soluble HBEGF that can 
bind ERBB1 and ERBB4 to generate intracellular signaling (Holbro and Hynes, 2004).  
Therefore, low O2 and HIF signaling could induce transcription of a metalloproteinase 
that sheds HBEGF to initiate autocrine signaling required for HBEGF accumulation.  
Microarray analysis of RNA from CTB cells cultured at 2% or 20% O2 for 1, 2, or 4 h 
identified several transcripts that mediate metalloproteinase function that were 
differentially altered by low O2, including basigin (BSG), a disintegrin and 
metalloprotease 10 (ADAM10), ADAM15, ADAM9, matrix metalloproteinase 2 (MMP2), 
and MMP15 (Table 4.2). ADAM9 and ADAM10 decreased during exposure to low O2, 
while the other transcripts increased. Most notably, MMP2 increased significantly (p = 
0.056) by over 40-fold after 4 h.  Subsequent qPCR analysis confirmed the increased 
expression and indicated that ADAM9 and ADAM10 actually were upregulated by low 
O2 in CTB cells (Table 4.3).  According to qPCR, MMP15 and MMP2 were maximally 
elevated 5.67 and 4.37 fold, respectively, at 4 h.  
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Table 4.2.  Transcription of metalloproteinases 
at 2% O2 in HTR-8/SVneo cells as detected by 
microarray.   
 Fold Change in Signal 
 2% O2 1h 2% O2 2h 2% O2 4h 
BSG 1.56* 2.01* 2.61* 
ADAM10 -1.22 -1.45* -2.41 
ADAM15 2.09* 2.42* 2.86* 
ADAM9 -1.42* -1.89* -2.16* 
MMP2 3.36 5.85 41.71* 
MMP15 1.40* 1.85* 2.71* 
 
Microarray analysis for metalloproteinase genes identified several transcripts 
upregulated in CTB cells cultured at 2% O2 for 1 - 4 h as compared to 20% O2.  
Asterisks indicate significant values (p < 0.1) according to microarray analysis 
compared to signal at 20% O2. 
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Table 4.3.  Expression of metalloproteinases at 
2% O2 in HTR-8/SVneo cells measured by qPCR. 
 Fold Change in Relative Expression 
 2% O2 1h 2% O2 2h 2% O2 4h 
BSG 2.13 ± 0.10 3.69 ± 2.55 3.74 ± 1.43 
ADAM10 3.60 ± 2.73 4.03 ± 3.16 2.84 ± 1.00 
ADAM15 3.17 ± 2.25 5.38 ± 4.31 2.89 ± 1.37 
ADAM9 4.70 ± 3.88 3.86 ± 3.03 2.98 ± 1.05 
MMP2 1.59 ± 0.41 5.56 ± 3.80 4.37 ± 2.03 
MMP15 7.58 ± 6.76 3.75 ± 2.14 5.67 ± 3.25 
 
QPCR was performed using the same RNA submitted for microarray analysis and two 
experimental repeats.  Values for metalloproteinase genes represent averages (n = 3) ± 
standard error, normalized to SDHA expression.  Several genes were upregulated in 
CTB cells cultured at 2% O2 for 1 - 4 h as compared to 20% O2.   
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MMP2 is Required to Increase HBEGF 
To determine whether MMP2 has a functional role in HBEGF regulation by O2, 
specific inhibitors of MMP2 and MMP9 were used to supplement culture medium during 
manipulation of O2 levels.  Unlike MMP2, MMP9 expression did not change at 2% O2, 
according to microarray analysis.  CTB cells cultured at 2% O2 for 4 h failed to 
accumulate HBEGF in the media when MMP2 was inhibited (Table 4.4).  However, 
MMP9 inhibition had no effect on the normal accumulation of HBEGF at low O2.  A third 
inhibitor that targets both MMP2 and MMP9 also inhibited HBEGF accumulation. We 
conclude that MMP2, but not MMP9, may directly or indirectly mediate the proteolytic 
cleavage of proHBEGF under control of O2 and O2-sensitive HIF transcription factors. 
The initiation of HBEGF shedding, in turn, allows it to bind ERBB receptors and 
precipitate autocrine signaling, as previously demonstrated using a less specific inhibitor 
of metalloproteinase activity (Armant et al., 2006). MMP15, which is also upregulated at 
2% O2 (Table 4.2 and 4.3), can activate MMP2 (Hitchon et al., 2002; Mohammad et al., 
2010), suggesting that MMP15 could cleave proMMP2 in a proteinase cascade that 
initiates HBEGF shedding.  
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Table 4.4.  Inhibition of MMP2 prevents 
HBEGF upregulation at 2% O2.   
% O2 Treatment 
HBEGF 
(pg/µg) 
20 Vehicle 1.01 ± 0.54 
2 Vehicle 46.41 ± 3.22 
2 MMP2/9 Inh. 1.11 ± 0.53 
2 MMP2 Inh. 1.07 ± 0.63 
2 MMP9 Inh. 58.15 ± 8.74 
 
HBEGF protein was measured by ELISA in the media covering CTB cells cultured for 4 
h at either 20% or 2% O2 in the presence of inhibitors of MMP2 and/or MMP9, as 
indicated.  The upregulation of HBEGF seen after culturing CTB cells at 2% O2 was 
abrogated by adding an inhibitor specific for MMP2 or an inhibitor of both MMP2 and 
MMP9.  An inhibitor of MMP9 alone does not block the increase in HBEGF due to 
culture at 2% O2.  Values are represented as average ± SEM. 
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DISCUSSION 
The regulation of HBEGF expression during implantation and placentation is 
critical for trophoblast survival and invasion.  An autocrine, post-transcriptional 
mechanism induced at low O2 upregulates HBEGF synthesis and secretion, providing 
an important survival factor during early gestation (Armant et al., 2006; Jessmon et al., 
2009).  The present study provides evidence that a transcriptional event is required to 
initiate the increased HBEGF synthesis downstream of HIF signaling.  It was 
hypothesized that HIF directs the transcription of a metalloproteinase that is directly or 
indirectly responsible for cleavage of transmembrane proHBEGF from the cell surface, 
initiating the autocrine feedback loop that increases HBEGF protein synthesis.  
Transcriptome analysis and qPCR validation implicated a protease cascade that 
includes MMP15 and MMP2 in HBEGF shedding.  Finally, a functional role for MMP2 in 
the accumulation of HBEGF was established using a specific inhibitor.  A mechanism is 
proposed wherein low O2 concentrations, as experienced by trophoblasts during the first 
10 weeks of placentation, induce HIF-mediated transcription of MMP2 that participates 
in a protease cascade to shed HBEGF from the cell surface, possibly with its activation 
by MMP15 (Hitchon et al., 2002; Mohammad et al., 2010), to commence the autocrine 
HBEGF signaling that increases its biosynthesis using a constitutively-expressed pool of 
HBEGF mRNA.   
HIF proteins are stabilized at low O2 (Wang and Semenza, 1993) and activate 
transcription of targeted genes by interacting with specific hypoxia response elements 
(HREs) in the gene promoters (Semenza, 2003).  Although they often have similar 
effects, HIF1α and HIF2α also have distinct functions.  In apoptosis, HIF2α may be 
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more important in protecting against environmental stressors and HIF1α may have a 
greater role in protecting against hypoxic damage (Brusselmans et al., 2001).  HIF3α 
appears to be a dominant negative inhibitor of HIF1α that binds HIF1α and prevents 
binding to HRE motifs (Makino et al., 2001). HIF3α was not increased by low O2 
treatment of CTB cells.  We suspected that either HIF1α or HIF2α may be involved in 
the response of CTB cells to low O2, based on their accumulation with CoCl2 or 2% O2 
treatment. Hence, HIF proteins would be capable of regulating the shedding and 
subsequent accumulation of HBEGF protein during the first 10 weeks of gestation and 
in our experimental model.  Others have examined the expression of HIFs in the human 
placenta and found that both HIF1α and HIF2α mRNA are expressed throughout 
gestation, though HIF2a mRNA tends to increase as gestation progresses (Rajakumar 
and Conrad, 2000).  Interestingly, protein expression for both, which is localized to 
trophoblast cells, is high in earlier stage placentae (5-11 weeks) when O2 is low, but 
declines at later gestational ages (Caniggia et al., 2000; Rajakumar and Conrad, 2000).  
At 20% O2, HIF1α mRNA and protein are upregulated in the EVT cell line TCL1 
(Fukushima et al., 2008), suggesting a continued role after O2 levels rise at the end of 
the first trimester. HIF1α can be activated by growth factor signaling, independently of 
O2 concentrations (Semenza, 2003).  HIF1α upregulates VEGF protein and causes 
integrin αVβ3 to aggregate in TCL1 cells, which leads to tube formation on Matrigel 
(Fukushima et al., 2008).  
MMP2 appeared to be among the genes that were transcriptionally regulated at 
low O2 and could be involved in a proteolytic cascade that culminates in HBEGF 
shedding.  Additionally, studies of early placentation suggest that MMP2 is important in 
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trophoblast invasion (Staun-Ram et al., 2004).  MMP2 protein and mRNA predominates 
in early first trimester trophoblasts and declines by the end of the first trimester, 
whereas MMP9 has the exact opposite pattern (Staun-Ram et al., 2004; Xu et al., 
2000).  MMP2 exists in a proteolytic cascade in αT3-1 cells that leads to both 
proHBEGF shedding and EGFR transactivation (Roelle et al., 2003).  In addition, its 
rapid release in CMTC9 cells after E2 stimulation is correlated with cleavage of 
proHBEGF (Torres et al., 2009).  Bradykinin-induced proliferation of rabbit corneal cells 
is blocked by an inhibitor of both MMP2 and MMP9 or an inhibitor of HBEGF, 
suggesting that either MMP may be involved in the cleavage of proHBEGF (Cheng et 
al., 2011).  In the present study, lack of a regulatory role for MMP9 in HBEGF 
expression at low O2 was supported by inhibitor experiments that showed MMP9 not to 
be essential for HBEGF upregulation.  Interestingly, low O2 (0.1%) increases MMP2 
mRNA in CTB cells isolated from first trimester placentae, but, in contrast to our 
findings, MMP2 secretion and enzymatic activity increase at 20% O2 relative to CTB 
cells cultured at 5% O2 (Onogi et al., 2011).  Culture at 2% O2 could differ significantly 
from 5% O2, and account for the different outcomes.  Differential gene expression 
studies suggested that MMP15 could contribute to a proteolytic cascade that activates 
MMP2.  Indeed, the MMP15 promoter contains two HREs (Zhu et al., 2011).  MMP15 
expression in psoriatic skin biopsies and bladder cancer tissue correlates with an 
increase in MMP2 proteolytic activity (Hitchon et al., 2002; Mohammad et al., 2010).  
MMP15 is a membrane-type matrix metalloproteinase (MT2-MMP) that can anchor 
MMP2 in the proximity of proHBEGF on the cell surface.  Additionally, tissue inhibitors 
of metalloproteinases (TIMPs), which are also present during CTB invasion (Niu et al., 
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2000; Onogi et al., 2011; Ruck et al., 1996), MT1-MMP and MMP2, facilitating their 
proteolytic activity (Butler et al., 1998).  A similar mechanism (Strongin et al., 1995) 
should exist for MMP15 and MMP2.  A specific inhibitor of MMP15 was not available to 
further explore its functional role; however, its expression pattern suggests that MMP15 
operates upstream of MMP2 in a proteolytic cascade that leads to proHBEGF cleavage. 
Other metalloproteinases, including members of the ADAM family, been 
implicated in the shedding of proHBEGF.  Like MT-MMP subfamily members, ADAM 
metalloprotases are membrane anchored (Edwards et al., 2008) and could direct 
protease activity towards the cell surface where proHBEGF resides.  Although an 
increase was detected in ADAM15 in CTB cells cultured at 2% O2, its function in 
implantation is currently unknown.  Low O2 upregulated ADAM9, ADAM10 and ADAM15 
in human CTB cells, according to qPCR results. Activation of metalloproteinases with 
APMA leads to shedding of HBEGF, but not in TACE-/- cells, indicating that 
TACE/ADAM17 proteolytically cleaves proHBEGF (Merlos-Suarez et al., 2001).  
TACE/ADAM17 transfected into TACE-deficient cells increased shedding of HBEGF 
(Sunnarborg et al., 2002).  ADAM17 was found to preferentially shed ERG, TGFα, 
AREG, and HBEGF.  However, microarray results showed no significant change in its 
transcription at low O2 (data not shown).  ADAM9 can direct the TPA-induced shedding 
of proHBEGF (Izumi et al., 1998).  In that study, PKCδ binds the intracellular domain of 
ADAM9 and brings it towards HBEGF to induce cleavage.  In mouse embryonic 
fibroblasts generated from ADAM knockout mice, it was discovered that ADAM10 
preferentially sheds EGF and BTC (Sahin et al., 2004).  In human epithelial cells, 
lipoteichoic acid, a major polysaccharide in Gram-positive cell walls) induces ADAM10 
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to cleave proHBEGF, which subsequently binds ERBB1 and induces signaling 
(Lemjabbar and Basbaum, 2002).  In COS7 cells transfected with mouse ADAM10, 
activation of GPCR leads to ADAM10-mediated shedding of HBEGF, which activates 
ERBB1 and the downstream Ras/Erk pathway (Yan et al., 2002).  It is interesting that 
qPCR results demonstrated that ADAM10 was upregulated by low O2.  ADAM12, 
another candidate sheddase for HBEGF, was not transcriptionally regulated, according 
to the microarray results (data not shown) (Asakura et al., 2002; Kurisaki et al., 2003).  
It is possible that ADAMs, particularly ADAM10, participate in the cascade that leads to 
shedding of HBEGF. 
Basigin (BSG/CD147/EMMPRIN) is a transmembrane immunoglobulin 
superfamily member that is critical in embryo implantation and is expressed in the 
blastocyst and endometrium of mice and rats (Ding et al., 2002; Igakura et al., 1998; 
Xiao et al., 2002b).  In the mouse, its expression is localized in the decidua surrounding 
an implanted blastocyst, and in the embryo (Xiao et al., 2002a), and BSG-/- mice fail to 
survive past implantation (Igakura et al., 1998).  Recombinant BSG induces MMP3 and 
MMP9 transcription, secretion and activity in a mouse uterine stromal cell culture, but 
has no effect on MMP2 (Chen et al., 2009).  It is possible that BSG expression by 
human trophoblasts targets metalloproteinases that participate in a proteolytic cascade 
to generate HBEGF shedding. 
Mechanisms regulating HBEGF synthesis in CTB cells are critical in early 
pregnancy. HBEGF prevents apoptosis at low O2 and stimulates motility at high O2 in 
first trimester trophoblasts (Jessmon et al., 2010; Leach et al., 2004a).  We have 
established a role for HIF1α and HIF2α in the regulation of HBEGF protein at low O2, 
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and suggest that HIFs may also have a role at high O2, highlighting the fact that they 
are an important transcription factor in regulating early trophoblast development.  In 
addition, evidence obtained using CoCl2 and mRNA expression analysis suggested that 
MMP2 is a HIF-regulated gene involved in HBEGF shedding.  These findings suggest 
that low O2 concentrations during early pregnancy induce a HIF-mediated increase in 
metalloproteinase activity that sheds HBEGF from the cell surface of CTB cells.  
HBEGF then signals in an autocrine loop to increase its synthesis, stimulate trophoblast 
motility, and block apoptosis. 
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CHAPTER 5.  Translational Regulation of HBEGF in Developing Human 
Trophoblast Cells 
SUMMARY 
Heparin-binding EGF-like growth factor (HBEGF) prevents apoptosis of human 
trophoblast cells exposed to low oxygen, as occurs in early pregnancy, and is 
dramatically upregulated in vitro by 2% O2 within 4 h without a change in HBEGF 
mRNA. Signaling through mitogen activated protein kinases (MAPKs) downstream of 
HBEGF is required for HBEGF protein accumulation, but the underlying post-
transcriptional mechanism is not understood further. HBEGF mRNA was stable up to 6 
h, suggesting that protein does not accumulate due to changes in mRNA degradation 
rates. Although HBEGF protein turnover was higher at 20% O2, stablilizing the protein 
with proteosome inhibitors was insufficient to increase cellular HBEGF, suggesting that 
HBEGF mRNA is translationally regulated by O2, perhaps through elements in its 3’ 
untranslated region (UTR). A dual luciferase reporter construct containing the intact 
HBEGF 3’UTR or specific subregions was implemented to examine its translational 
regulatory potential.  The intact 3’UTR reduced luciferase activity to approximately 30% 
(p<0.05). However, the isolated flanking regions increased reporter activity 4- to 5-fold 
(p<0.05), while two central domains modestly repressed reporter (~50%, p<0.05). The 
possible role of microRNA (miRNA) in the targeted regulation of HBEGF was examined 
by RNAi knockdown of the miRNA-processing protein, DGCR8. Knockdown of the 
DGCR8 protein correlated with reduced HBEGF labeling on western blots, suggesting 
that miRNA is required to maintain or stimulate HBEGF translation. Secondly, the 
abundance of 30 individual miRNAs predicted to target the HBEGF 3’UTR were 
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examined at both 20% and 2% O2 by TaqMan qPCR, revealing no significant change in 
their expression. It is concluded that HBEGF is not transcriptionally or post-
translationally regulated by O2 in human trophoblast cells, but is translationally 
regulated through the interaction of miRNA with the HBEGF 3’UTR. It appears that the 
3’UTR contains flanking elements that interact with miRNA to increase HBEGF 
translation, and that other 3’UTR domains attenuate the flanking region activity.  
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INTRODUCTION 
The epidermal growth factor (EGF) family member, heparin binding EGF-like 
growth factor, (HBEGF), is present in the uterus at the time of embryo implantation 
(Leach et al., 1999b; Yoo et al., 1997a), and its expression in cytotrophoblast (CTB) 
cells of the invading placenta indicate its central role in early implantation and 
subsequent placentation (Leach et al., 2002a).  It is one of the earliest growth factors 
expressed in mice just prior to implantation, is localized in uterine cells surrounding an 
implanted embryo, and is found subsequently in the underlying uterine decidua of mice, 
human, and non-human primates (Das et al., 1994c; Leach et al., 2001; Leach et al., 
1999b; Yue et al., 2000).  In the human uterus, HBEGF is upregulated during the 
window of implantation.  The implantation site in humans is a low O2 environment, as 
the placenta is not fully oxygenated until after the 10th week of pregnancy when 
occluding CTB plugs within the uterine spiral arteries are dislodged and maternal blood 
flows freely into the intervillous space (Burton and Jauniaux, 2004; Burton et al., 1999; 
Jauniaux et al., 2001b; Rodesch et al., 1992).  Previous in vitro work has demonstrated 
that HBEGF protein levels are dramatically upregulated in CTB cells cultured at low O2 
(2%), which simulates in utero O2 concentrations during the first trimester (Armant et al., 
2006).  Other EGF family members are not altered by changes in O2 concentration.  
Notably, trophoblast cells do not undergo apoptosis upon exposure to a sudden 
elevation of O2 after the 10th week, but continue to invade into the uterine decidua.  In 
vitro, HBEGF protects first trimester CTBs from apoptosis and promote their invasion 
(Armant et al., 2006; Leach et al., 2004a).  Hence, its upregulation by low O2 during the 
first trimester may protect trophoblast cells from oxygenation during increased maternal 
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blood flow, as well as induce invasion into the uterine decidua.  The syndrome 
preeclampsia, in which trophoblast invasion is dramatically reduced and apoptosis is 
elevated, is characterized by a dramatic reduction in placental HBEGF protein levels 
(Leach et al., 2002a).   
Previous work has established that HBEGF mRNA is not transcriptionally 
regulated by O2 in human trophoblast cells (Armant et al., 2006).  Even though protein 
translation is often globally downregulated by hypoxia (Koumenis et al., 2002), HBEGF 
protein levels increase dramatically at low O2.  HBEGF upregulation occurs downstream 
of its autocrine signaling.  ProHBEGF on the cell surface is proteolytically cleaved, 
allowing soluble HBEGF to bind its ERBB receptors and initiate intracellular signaling 
that, among other things, increases its own protein by a post-transcriptional mechanism.  
This autocrine mechanism is likely initiated by metalloproteinases upregulated at 2% 
O2, such as MMP2, that target proHBEGF for cleavage (Chapter 4). 
The post-transcriptional regulation of HBEGF could be directed by mRNA 
stability, protein turnover, or a specific translational regulatory step.  Examples exist 
where mRNA transcripts are destabilized in one condition, leading to a decrease in 
protein levels (Baudouin-Legros et al., 2005; Phelps et al., 2006), and stabilized in 
another condition (Zhao et al., 2008), leading to protein accumulation.  A prior study has 
shown that HBEGF mRNA is stabilized in HeLa cells induced to undergo cellular stress 
by a chemotherapeutic agent (Sorensen et al., 2006).  However, because HBEGF 
transcript levels are not altered by O2 fluctuations (Armant et al., 2006), it is unlikely that 
mRNA stability is a factor in its regulation.  Regulation of transcription and translation 
can be disparate processes, depending on the gene and cellular context (Koritzinsky et 
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al., 2005; Yukawa et al., 1999).  It is possible that HBEGF proteolysis is inhibited by 2% 
O2, leading to its accumulation.  This mechanism suggests that HBEGF is synthesized 
and constitutively degraded at 20% O2, but is stabilized at low oxygen.  However, it can 
also be hypothesized that its accumulation is not simply due to an inhibition of its 
proteolysis, but to a regulation of its translation.  Indeed, the maintenance of HBEGF 
transcripts in a pool stable at both 20% and 2% O2 (Armant et al., 2006) suggests that 
its translation is initiated at low O2, and perhaps inhibited by high O2. 
MicroRNAs (miRNAs) are ~22 nt endogenous small RNA species that primarily 
target the 3’ untranslated region (3’UTR) of mRNA transcripts to suppress translation 
(Kim and Nam, 2006; Pillai et al., 2007).  They are transcribed as primary miRNA 
transcripts in the nucleus by RNA Polymerase II and are subsequently processed by the 
nuclear proteins Drosha and DGCR8 into shorter pre-miRNA hairpin precursors.  These 
pre-miRNAs are exported into the cytoplasm and processed into the mature ~22 nt form 
by Dicer (Bartel, 2004).  A mature miRNA is incorporated into an RNA-induced silencing 
complex (RISC) or miRNP (miRNA ribonucleoprotein) where it binds with perfect 
complementarity to a conserved 6-8 nt seed region in the 3’ UTR.  MiRNAs have the 
unique capacity to bind a specific target transcript and, due to imperfect base pairing at 
nucleotides 10-11, inhibit translation without acting as siRNA and inducing degradation 
of the mRNA (Bartel, 2004; Filipowicz et al., 2008; Pillai et al., 2007).  In effect, they 
mediate a very rapid and energetically efficient regulatory mechanism that occurs only 
at the translational level.  Recent evidence demonstrating upregulation of TNFA 
translation during cell cycle arrest (Vasudevan et al., 2007) suggests that miRNAs may 
also upregulate translation.  Hence, a miRNA-mediated mechanism could be 
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responsible for the translational suppression of HBEGF at higher O2 concentrations or 
induction of its translation at low O2.  In the placenta, miRNAs could rapidly regulate 
HBEGF in response to sudden changes in O2 level, growth factor signaling or 
extracellular matrix composition experienced by developing trophoblast cells. 
Specific miRNAs are expressed in placental tissues (Barad et al., 2004; Maccani 
and Marsit, 2009; Mouillet et al., 2011) and in trophoblast cells (Donker et al., 2007; 
Spruce et al., 2010) that target proteins important for trophoblast physiology.  MiR-152 
targets HLA-G in JEG3 cells (Zhu et al., 2010), miR-34a targets Notch1 and Jagged1 in 
HeLa and JAR cells (Pang et al., 2010), and miR-199b targets SET (protein 
phosphatase 2A inhibitor) in BeWo and JAR cells (Chao et al., 2010).  Hence, it is 
feasible to hypothesize that miRNA that target HBEGF also exist in CTB cells.  A recent 
study (Donker et al., 2007) demonstrated that, in first trimester trophoblast cells, the 
miRNP machinery is present in cells cultured at 20% and 2% O2, and differential 
regulation of miRNAs silence MED1 expression.  Regulated expression of miRNAs that 
target HBEGF could likewise provide evidence that its translational suppression at 20% 
O2 is mediated by miRNAs. 
In this study, it was determined whether HBEGF protein is regulated by O2 
through a change in its stability, or if other post-transcriptional mechanisms are at work.  
We specifically examined the regulatory function of the 3’UTR of HBEGF and the role of 
miRNA species in the translational control of HBEGF. 
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MATERIALS & METHODS 
Cell Culture and Treatments 
The first trimester human cytotrophoblast cell line HTR-8/SVneo (Graham et al., 
1993b) was cultured at either 20% O2 or 2% O2 as previously described (Leach et al., 
2004a; Leach et al., 2008b).  Cells were cultured for the indicated times in 1-5 µg/mL α-
amanitin, an inhibitor of RNA Polymerase II that blocks de novo transcription (Sigma-
Aldrich), in 250 µM CoCl2 (Sigma-Aldrich) to increase HIF at 20% O2, in 10 µg/mL 
cyclohexamide to block de novo translation (Sigma-Aldrich), and in 1 µg/mL lactocystin 
or 100 µg/mL MG132 to inhibit the proteasome (EMD Biosciences). 
qPCR 
RNA from HTR-8/SVneo cells was collected using the miRNeasy kit from 
Qiagen, according to the manufacturer’s protocol.  RNA concentration was determined 
using the NanoDrop spectrophotometer and purity was ascertained with an Agilent 
Bioanalyzer (Agilent).  Reverse transcription was performed using the Quantitect 
Reverse Transcription kit (Qiagen) and qPCR (Bustin et al., 2009) was conducted with 
the Quantitect SYBR Green PCR kit without UNG in a final volume of 25 µL.  An 
appropriate housekeeping gene was chosen from a panel of genes used for all samples 
(RRN18S, ACTB, GAPD, RPL13A, RPLP0, SDHA).  For each experiment, the 
housekeeping gene with the least variability among all treatments was selected for 
normalization in subsequent qPCR experiments.  For CoCl2 experiemnts, RPL13a 
(ribosomal protein 13a) was chosen, and for all other experiments, SDHA (succinate 
dehydrogenase) had the least variability.  Semi-quantiative analysis was performed 
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using the ΔΔCt method (Pfaffl, 2001).  Primers for the housekeeping genes and for 
HBEGF were obtained from Qiagen. 
Western Blotting 
Western blots were performed as previously described (Kilburn et al., 2000b).  
Cellular lysates were diluted in SDS sample buffer containing 5% β-mercaptoethanol, 
run on precast 4%–20% Tris-HCl gradient gels (BioRad), and transferred to 
nitrocellulose membranes.  Monoclonal mouse antibodies against DGCR8 (0.3 µg/mL, 
Proteintech) and GAPDH (1 µg/mL, Ambion) were diluted in TTBS containing 5% milk.  
A polyclonal antibody against HBEGF (R&D Systems) was diluted to 0.2 µg/mL in TTBS 
containing 5 mg/mL BSA. 
ELISA 
ELISA was carried out using the HBEGF DuoSet ELISA Development kit (R&D 
Systems), as previously described (Armant et al., 2006; Leach et al., 2008b). The 
optical density of the final reaction product was determined at 450 nm using a 
programmable multiplate spectrophotometer (Power Wave Workstation; Bio-Tek 
Instruments) with automatic wavelength correction. 
Generation of 3’UTR Luciferase Reporter Vectors 
Regions of the HBEGF 3’UTR were amplified by PCR and cloned into the 
PsiCheck-2 vector (Promega).  This vector is unique in that two different luciferase 
genes (Firefly and Renilla) driven by two different promoters are present in the same 
vector.  The Renilla gene serves as a reporter and the Firefly gene as an internal 
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control.  HBEGF 3’UTR-derived inserts were cloned into a region immediately following 
the Renilla luciferase gene.  Lyophilized primers (IDTDNA) used to amplify regions of 
the HBEGF 3’UTR were designed using Primer3 software ((Rozen and Skaletsky, 2000) 
in (Krawetz and Misener)) and aligned against the human transcriptome for specificity 
(NCBI BLASTN).  Three adenosine nucleotides and restriction enzyme recognition 
sequences for XhoI and NotI were added to forward and reverse primers, respectively 
(Table 5.1).  Secondary structure, primer dimers, and self-annealing were examined 
using OligoCalc (Kibbe, 2007).  Regions amplified by these primers and expected 
amplicon sizes are listed in Table 5.1.  After isolating RNA, cDNA was generated using 
the Omniscript Reverse Transcription kit (Qiagen).  HBEGF 3’UTR fragments were 
amplified by endpoint PCR using the HotStarTaq Plus Master Mix kit (Qiagen) 
according to the manufacturer’s instructions with the following formulation.  In a total 
reaction volume of 50 µL, 0.5 µM of each primer and 50 ng of cDNA was used.  
Amplicon size was verified with 8 µL of the final PCR reaction assessed by 0.8% 
agarose gel electrophoresis.  If amplicons were of the expected size, the remaining 42 
µL of PCR products were processed using the Wizard SV Gel and PCR Clean-up Kit 
(Promega).  In all restriction enzyme reactions, components were combined, gently 
mixed, and briefly centrifuged.  Cleaned amplicon and the PsiCheck2 vector (1 µg each) 
were digested in 0.2 mL thin-walled tubes (Molecular BioProducts) with both XhoI and 
NotI restriction enzymes (Promega) at the recommended concentration for 1 h at 37°C 
in Buffer D (supplied by Promega) in a thermal cycler, followed by a 15 min 70°C 
inactivation step.  Cut PsiCheck2 vector was then treated with 1 µL thermosensitive 
alkaline phosphatase (Promega) for 15 min, followed by a 15 min heat inactivation step.   
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 Table 5.1.     Primer sequences for amplification of HBEGF 3’UTR and vector 
sequencing. 
 
Forward 
Primers 
Sequence Target Site on 
HBEGF mRNA 
HBEGF 3’UTR AAACTCGAGGGAGGTTATGATGTGGAAAATGA 844 
HBEGF 3’UTR AAACTCGAGCCTTTGCCACAAAGCTAGGA 1644 
HBEGF 3’UTR AAACTCGAGTTGCCTAGGCGATTTTGTCT 1829 
HBEGF 3’UTR AAACTCGAGAACAGGGAACATTGGAGCTG 2137 
PsiCheck-2 
vector 
AGGACGCTCCAGATGAAATG  
   
   
   
   
Reverse 
Primers 
Sequence Target Site on 
HBEGF mRNA 
HBEGF 3’UTR AAAGCGGCCGCAGATCCCTTGGTGGTACT 1363 
HBEGF 3’UTR AAAGCGGCCGCCAGGAAATTGCCAAAGTA 1603 
HBEGF 3’UTR AAAGCGGCCGCCCAAGTTAACCCCTACATCCTG 1778 
HBEGF 3’UTR AAAGCGGCCGCATGAACCAGGTTTGGAAATACA 2315 
PsiCheck-2 
vector 
CAAACCCTAACCACCGCTTA  
 
Primer sequences for amplification of the HBEGF 3’UTR and sequencing of the 
psiCheck2 vector are listed along with their binding locations. 
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Restricted amplicons and PsiCheck2 vector were combined in a 2:1, 4:1, or 6:1 ratio in 
a ligation reaction using Promega’s LigaFast Rapid DNA Ligation System for 2 h at 
37°C in a thermal cycler.  To verify ligation, 1 µL of ligated product was then added to 
an endpoint PCR reaction mixture using primers that bind outside of the PsiCheck2 
vector’s multiple restriction site, as indicated in Table1.  If the PCR reaction produced 
an appropriately-sized amplicon, the ligation reaction was used in subsequent bacterial 
transformations. 
Bacterial Transformation  
One microliter of the ligation reaction mixture was added to a sterile 15 mL round 
bottom, thin-walled culture tube and placed on ice.  50 µL of JM109 bacteria (Promega) 
were added to each culture tube, directly on top of the ligation product.  1 µL of empty 
PsiCheck2 vector that had been cut with restriction enzyme and treated with alkaline 
phosphatase was also transformed into bacteria as a negative control.  After a 2 min 
incubation on ice, bacteria were heat shocked by immersing in a 37°C water bath for 
50-55 sec, and the incubating on ice for 10 min.  Next, 950 µL of ice-cold SOCs media 
(Invitrogen) was added to each culture tube before incubation at 37°C with gentle 
agitation (200 rpm) for 90 min.  After 200 µL of the bacterial mixture was added to an LB 
Agar plate containing AMP-100, X-GAL-80, and IPTG-50 (Teknova), it was incubated 
upright overnight at 37°C.  Colonies were picked with sterile 10 µL pipette tips that were 
gently dabbed onto an agar plate and placed in 3 mL of LB broth (Becton, Dickinson & 
Co.) containing 100 µg/mL of Ampicillin.  After culturing at 37°C overnight with gentle 
agitation (200 rpm), 100 µL of each bacterial mixture was drawn off, pelleted at 7500 
rpm for 5 min in a 1.5 mL microcentrifuge tube, and resuspended in nuclease-free water 
	   117 
(IDTDNA).  Resuspended bacteria were then heated to 100°C for 10 min, and 1 µL of 
the resulting lysate was added to an endpoint PCR reaction using the same primers 
utilized to verify ligation.  PCR products were electrophoresed on 0.8% agarose gels, 
and those colonies that displayed the presence of a correctly-sized insert and no empty 
vector (as evidence by amplification of a ~220 bp fragment) were chosen for vector 
recovery using the Wizard Plus SV Miniprep Kits (Promega).  Vectors were diluted to 
100 ng/µL in nuclease-free H2O and 1 µL was used in subsequent transfection 
reactions.  Vectors were sequenced using the same primers utilized to verify ligation 
and aligned to the HBEGF mRNA sequence (PUBMED sequence NM_0001945.2) 
using Geneious (Drummond et al., 2011). 
Transfection and Luciferase Assay 
HTR-8/SVneo cells were grown to 75% confluency in 6-well culture plates 
(Falcon, #353046).  Media was replaced with serum-free media (DMEM/F-12 with 5 
mg/mL BSA) containing transfection reagents and cells were cultured for 24 hr.  To 
prepare transfection reagents, room temperature FuGene-6 transfection reagent (Roche 
Diagnostics) was added to unsupplemented DMEM/F-12 media in a 1.5 mL 
microcentrifuge, gently mixed, and incubated at room temperature for 5 min.  Then, 100 
ng of vector was added with gentle mixing and incubated at room temperature for 15 
min.  It was determined that 3 µL of FuGene-6 and 1 µL of vector DNA (100 ng) was 
optimal per 6-well transfection.  The entire contents of each transfection mixture were 
then added dropwise to one well of the 6-well plate, and the plate was rocked to ensure 
proper mixing.  After a 24 h incubation at 37°C, the media was removed, the cells were 
washed twice with 1X PBS and they were lysed in 500 µL 1X passive lysis buffer 
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(Promega) for 15 min on an orbital plate shaker at room temperature.  Lysates were 
centrifuged at 5000 rpm for 5 min to remove cellular debris and 20 µL supernatant was 
used in each dual luciferase reaction, conducted according to the manufacturer’s 
protocol (Dual Luciferase Reporter Kit, Promega) in a 96-well plate with a clear, flat 
bottom.  Negative controls consisting of 20 µL passive lysis buffer and untransfected 
cells were also included.  Each sample received 100 µL of Luciferase Assay Reagent II 
reagent using a multichannel pipette.  The plate was placed in a Veritas microplate 
luminometer (Turner BioSystems) and automated measurements were obtained after 
exactly 1 min, and five more times at regular intervals.  Then, 100 µL of Stop & Glo 
reagent (Promega) was added to each sample.  Five automated measurements were 
then obtained at regular intervals beginning 1 min after addition of the second reagent.  
Renilla luciferase activities were normalized to corresponding Firefly luciferase activities 
at each of the five intervals, and an average ratio was calculated.  Each transfection 
experiment was repeated at least three times. 
Custom TaqMan miRNA qPCR Plates 
Custom 96-well plates containing lyophilized real time primers and probes for the 
27 miRNA listed in Table 5.2 were obtained from Applied Biosystems.  RNA samples 
collected using the miRNeasy kit were reverse transcribed using ABI miRNA-specific 
RT primers, mixed with Universal PCR Master Mix and transferred to the 96-well 
custom plates preloaded with real time primers	   (Applied Biosystems), as directed by 
ABI.  Samples were amplified in an Applied Biosystems 7500 Fast real-time thermal 
cycler using a protocol provided by the custom plate manufacturer.  Results were 
analyzed according to the ΔΔCt method (Pfaffl, 2001), using RNU48 as a housekeeping 
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control gene.  Samples from five independent experiments (n=5) were used to 
determine the mean ± SEM. 
Bioinformatics 
A recent study suggestd that TargetScan is among two of the best miRNA target 
site prediction programs as it is considers site conservation more strictly (Baek et al., 
2008).  Both miRBase (Griffiths-Jones, 2004; Griffiths-Jones et al., 2006; Griffiths-Jones 
et al., 2008; Kozomara and Griffiths-Jones, 2011) and TargetScan (Friedman et al., 
2009; Grimson et al., 2007; Lewis et al., 2005) databases were searched for miRNAs 
that target HBEGF.  Several miRNAs were listed in both databases, and results were 
combined to produce the candidates shown in Table 5.2.  TESS (Schug and Overton, 
1997), Tfsitescan, and TFSEARCH (Heinemeyer et al., 1998) were used to examine 
transcription factor-binding elements in the promoter of HBEGF.  AREsite (Gruber et al., 
2011) was used to examine possible AREs in the 3’UTR.  EMBOSS GETORF was used 
to examine potential uORFs. 
DGCR8 Knockdown 
Three siRNAs that target DGCR8 were obtained from Life Technologies (s29061, 
s29062, s29063).  First, HTR-8/SVneo cells were tested for toxicity due to NeoFx 
reagent (Ambion) used to transfect the cells with siRNA.  Toxicity was measured using 
the MultiTox-Fluor Multiplex Cytotoxicity Assay kit (Promega) and an optimal 
concentration of NeoFx (0.75 µL per well of a 96-well plate) was determined (<10% 
toxicity after 48 hr).  Cells were transfected in 96-well plates (5,000 cells per well) for 48 
hr with various concentrations of each DGCR8 siRNA.  Cells were fixed with ice-cold 
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methanol for 10 min, incubated with 0.1% Triton-X100 for 15 min, stained overnight with 
a primary antibody against DGCR8 (Santa Cruz Biotechnology, Inc.) at 4°C, incubated 
for 1 hr at room temperature with an anti-mouse/anti-rabbit labeled polymer (DAKO 
EnVision Dual Link) and bound antibody visualized by light microscopy using a DAB 
chromogen. 
Statistics 
All experiments were repeated at least three times and are reported as mean ± 
SEM.  Statistical significance was determined at P < 0.05 by 2-way ANOVA, followed by 
post-hoc analysis with Dunnett’s t-tests, Student-Newman-Keuls and Student’s t-tests 
using SPSS version 12.0 statistics software (SPSS) and StatPlus:mac (Wang et al., 
2002). 
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RESULTS 
HBEGF mRNA is stable at 20% and 2% O2 
The presence of approximately 2500 copies of HBEGF mRNA at both 20% and 
2% O2 (Armant et al., 2006) suggests that the dramatic increase in HBEGF synthesis 
after 4 h of culture at 2% O2 is controlled post-transcriptionally.  To further examine the 
role of transcription, CTB cells were cultured at 20% or 2% O2 in the presence or 
absence of α-amanitin, an inhibitor of the RNA polymerase II enzyme.  Control cells 
were cultured in either 20% or 2% O2 for 6 h without inhibitor.  Cells treated with α-
amanitin were first treated for 1 h before exposure to the inhibitor for the indicated 
times.  The relative expression of HBEGF mRNA, normalized to SDHA mRNA, was 
determined by qPCR.  As expected, HBEGF mRNA levels in the absence of inhibitor 
were similar at 2% and 20% O2 (Fig. 5.1 A; p = 0.15 by Student’s t-test).  The presence 
of 1 µg/mL α-amanitin did not significantly alter the abundance of HBEGF transcripts in 
CTB cells cultured at 2% or 20% O2 for up to 6 h (p = 0.62 by ANOVA).  It was 
determined in previous experiments that HBEGF upregulation at 2% O2 is maximally 
inhibited by 2-10 µg/mL a-amanitin.  Therefore, higher concentrations of α-amanitin 
were tested, producing a similar lack of effect (Fig. 5.1 B; ANOVA p = 0.58).  CoCl2 
treatment for up to 4 h, which stabilizes HIF2α at 20% O2 (Jiang et al., 1997) to mimic 
low O2, had no significant effect on HBEGF transcript levels (Fig. 5.1 C; ANOVA p = 
0.45), although HBEGF protein levels increased dramatically (data not shown).  HBEGF 
mRNA levels were unaffected by the addition of α-amanitin (1.39-fold difference from no 
treatment), suggesting that CoCl2 also increases HBEGF protein levels post-
transcriptionally.  Therefore, transcription of HBEGF was not appreciably altered by O2  
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fluctuations or HIF, and remained stable in the absence of new transcription.  Therefore, 
alterations in the transcription or stability of HBEGF mRNA does not account for the 
observed accumulation of HBEGF protein during hypoxia. 
HBEGF Protein Accumulation is Not Regulated by Turnover Rate 
The observed increase in HBEGF protein levels at low O2 could reflect a change 
in protein stability where it is degraded more slowly at 2% O2.  To address this 
hypothesis, HBEGF protein levels were tracked after culture at 2% O2 for 6 h to 
increase HBEGF.  If translation was blocked with cyclohexamide while culture continued 
at 2% O2 for an additional 2 hours (Fig. 5.2 A), HBEGF levels remained unchanged.  In 
contrast, cells returned to 20% O2 showed a marked destabilization of HBEGF protein 
which decreases significantly within 15 min (Fig. 5.2 B).  HBEGF degradation was 
abrogated if cells were concomitantly treated with the proteasome inhibitors MG132 or 
lactocystin.  Although differential stability of HBEGF was observed at 2% and 20% O2, 
HBEGF protein did not increase at 20% O2 when cells were treated with proteasome 
inhibitors, indicating that stabilization of HBEGF degradation at 20% O2 is insufficient for 
its accumulation.  However, destabilization by proteolysis through the proteasome 
appears to have an important role in clearing HBEGF during reoxygenation. 
Translational Regulatory Activity of the HBEGF 3’UTR 
The absence of evidence for regulation of HBEGF by O2 through its transcription 
rate or the rate of mRNA or protein turnover suggested that it might accumulate due to 
an increased rate of translation.  The differential regulation of HBEGF synthesis could 
occur by suppressing or activating translation of its mRNA under the direction of its  
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large (1455 bp) 3’UTR, a region of mRNA known to be involved in transcript stability 
and translational control (Mignone et al., 2002).  To determine whether the 3’UTR of 
HBEGF can control translation, a PsiCheck-2 luciferase reporter with inserts of the 
entire HBEGF 3’UTR or its subdomains was prepared and transfected into CTB cells 
cultured at 20% O2.  The presence of certain portions of the HBEGF 3’UTR altered 
Renilla luciferase production, as compared to an empty vector control (Fig. 5.3).  A 
vector containing the full-length 3’UTR (844-2315) significantly (p = 0.008) repressed 
reporter activity, as did vectors containing the entire first half (844-1778; p = 0.031) or 
second half (1644-2315; p = 0.019) of the 3’UTR.  In contrast, the 134 bp region 
overlapped by the two half 3’UTR vectors did not regulate reporter activity.  Vectors 
containing regions 844-1603, 1644-1778, and 1829-2315 were also not active.  Vectors 
containing either the 5’ (844-1363) or 3’ (2137-2315) flanking regions of the 3’UTR 
upregulated Renilla luciferase activity at both 20% O2 and 2% O2 (p < 0.001 for both). 
Based on these observations, it appears that the two flanking domains of the 3’UTR 
increase translational activity when isolated from other 3’UTR sequences, while the 
presence of regions from 1363bp - 1644bp and 1778bp - 1829bp instigated translational 
suppression (Figure 5.6). 
Global Inhibition of miRNA Processing 
As specific regions of the HBEGF 3’UTR were found to be responsible for the 
suppression or activation of luciferase production, it can be hypothesized that miRNAs 
that interact with the 3’UTR are required for this regulation.  Therefore, the role of 
miRNA was examined by knocking down the miRNA-specific  
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processing protein, DGCR8, using siRNA.  Three different siRNAs designed to block 
DGCR8 expression were tested by western blotting for their ability to reduce DGCR8.  It 
was found that siRNA #1 inhibited DGCR8 maximally and addition of the other two 
siRNAs did not augment the response (Fig. 5.4 A-B).  However, knocking down DGCR8 
in CTB cells did not lead to an increase in HBEGF protein levels as expected if miRNA 
repressed HBEGF translation (Fig. 5.4 C).  Instead, the knockdown of DGCR8 with 
siRNA #1 led to a decrease in HBEGF protein levels, suggesting that miRNA could 
contribute to the upregulation of HBEGF synthesis at 2% O2. 
Differential Expression of miRNAs Predicted to Target the HBEGF 3’UTR 
Having established a role for miRNA in regulating HBEGF accumulation, it was 
hypothesized that 3’UTR interacting miRNAs are differentially expressed in response to 
O2 concentration in CTB cells.  Bioinformatics were employed to identify miRNAs that 
could potentially bind the 3’UTR of HBEGF.  Combining results from the miRBase 
database and TargetScan identified 27 miRNAs (Table 5.2).  Custom qPCR plates 
designed to screen the candidate miRNAs were used to examine their differential 
expression in cells cultured for 4 h at either 20% O2 or 2% O2 (Fig. 5.5).  All miRNAs 
except miR-581 and miR-623 were expressed in CTB cells.  However, the remainder of 
miRNAs, with the exception of hsa-miR-376c (p = 0.03), were expressed at levels that 
were not statistically different at high and low O2.  These findings demonstrate that none 
of the miRNAs were differentially expressed at the two O2 concentrations, suggesting 
that miRNAs targeting HBEGF are not transcriptionally regulated by O2.  Therefore, the 
mechanism that increases HBEGF translation does not appear to involve an alteration 
in any of the selected candidate miRNAs in response to O2 fluctuations. 
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Table 5.2.     MiRNAs that target HBEGF. 
 
 
Names, sequences and locations where the miRNAs are predicted to bind the 
HBEGF 3’UTR are listed.  
Name Sequence Target Site on 
HBEGF mRNA 
hsa-let-7d TCTCCATCATCCAACGTATCAA 911-932 
hsa-let-7f-1* GATATGTTAGATAACGGAAGGG 2173-2194 
hsa-let-7g ACTCCATCATCAAACATGTCAA 911-932 
hsa-let-7i ACTCCATCATCAAACACGACAA 910-932 
hsa-miR-27a AAGTGTCACCGATTCAAGGCG 1385-1405 
hsa-miR-27b AAGTGTCACCGATTCAAGACG 1385-1405 
hsa-miR-29a ATCGTGGTAGACTTTAGCCAAT 2026-2047 
hsa-miR-29b ATCGTGGTAAACTTTAGTCACAA 2025-2047 
hsa-miR-29c ATCGTGGTAAACTTTAGCCAAT 2026-2047 
hsa-miR-96 AAACCGTGATCGTGTAAAAACGA 1050-1072 
hsa-miR-128 AGTGTCACTTGGCCAGAGAAA 1399-1432 
hsa-miR-132 ATTGTCAGATGTCGGTACCAGC 1550-1571 
hsa-miR-132 ATTGTCAGATGTCGGTACCAGC 2110-2131 
hsa-miR-135a ATACCGAAAAATAAGGATACACT 1303-1324 
hsa-miR-135b ATACCGAAAAGTAAGGATACACT 1303-1324 
hsa-miR-182 AAACCGTTACCATCTTGAGTGTGA 1179-1202 
hsa-miR-183 ATACCGTGACCATCTTAAGTGA 2242-2263 
hsa-miR-194 ACATTGTCGTTGAGGTACACCT 1565-1587 
hsa-miR-194 ACATTGTCGTTGAGGTACACCT 2269-2290 
hsa-miR-203 CACTTTACAAATCCTGGTGATC 1548-1569 
mmu-miR-207 CGAAGAGGACCGAGAGGAGGGAG 2055-2077 
hsa-miR-212 ATTGTCAGAGGTCAGTGCCGG 1553-1571 
hsa-miR-376c TTGTATCTCCTTTAAGGTGCA 1492-1512 
hsa-miR-379 ACCATCTGATACCTTGCATCC 1800-1820 
hsa-miR-581 AGAACACAAGAGATCTAGTCA 816-836 
hsa-miR-623 TAGGGAACGTCCCCGACAACCCA 1326-1346 
hsa-miR-630 TCATAAGACATGGTCCCTTCCA 2221-2243 
hsa-miR-662 AGGGTGCAACACCGGGTCGTC 1957-1977 
hsa-miR-760 GCCGAGACCCAGACACCCCT 1755-1773 
hsa-miR-1271 GAACCGTGGATCGTTCGTGAGT 1065-1085 
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DISCUSSION 
Expression analysis and specific inhibition of HBEGF signaling established an 
autocrine, post-transcriptionally regulated increase in HBEGF synthesis and secretion in 
human trophoblast cells when the O2 concentration is reduced to 2% (Armant et al., 
2006). The upregulation of HBEGF at low O2 requires activation of its cognate receptors 
(ERBB1 and ERBB4) and downstream signaling through any one of three MAPK 
pathways (MAPK1/3, MAPK14 or MAPK8) (Jessmon et al., 2010). Several post-
transcriptional mechanisms were contemplated that could account for the regulation of 
HBEGF expression by O2. The stability of HBEGF mRNA could increase with reduced 
O2, as shown for the upregulation of NHE1 by EGF signaling through PI3K and MEK1/2 
pathways (Chiang et al., 2008).  IGF-1 induces stabilization of COX2 mRNA through 
sequences in its 3’UTR by activating the ERK1/2, p38, and PKC pathways (Cao et al., 
2007).  In G(0) growth arrested mammary epithelial cells, ultraviolet radiation activates 
p38 and translocation to the cytoplasm of the AU-rich element (ARE)-binding protein 
HuR (Brennan and Steitz, 2001), which stabilizes c/EBPdelta mRNA by binding AREs in 
its 3’UTR (Li et al., 2008). However, the steady state levels of HBEGF transcripts were 
similar at high and low O2 concentrations (Armant et al., 2006) and the message 
persisted for 6 h at both O2 levels when de novo transcription was inhibited by α-
amanitin. Alternatively, HBEGF protein could be degraded more rapidly at high O2 
concentrations and thus accumulate in low O2. Estrogen increases protein levels of 
CXCR4 without affecting a change in its mRNA (Sengupta et al., 2009).  An agonist of 
the liver X receptor (LXR) induced TNFA protein production without altering mRNA 
levels, and appeared to do so through the p38 signaling pathway (Wang et al., 2009b). 
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However, blocking HBEGF degradation with proteosome inhibitors failed to instigate its 
accumulation in trophoblast cells cultured at 20% O2, suggesting that the upregulation 
of HBEGF at low O2 is not due to decreased HBEGF turnover, but uses a mechanism 
that actively increases the translation of dormant HBEGF mRNA. HBEGF turnover was 
indeed strikingly faster at 20% than 2% O2, which could facilitate clearance of the 
protein during reoxygenation. 
Given the lack of transcriptional regulation, it was hypothesized that HBEGF 
translation could be regulated by regions in its large 3’UTR.  Luciferase reporter assays 
are a useful means to examine translational regulation by 3’UTR sequence (Pang et al., 
2009) and provide evidence that specific regions of the HBEGF 3’UTR regulate its 
translation with stimulatory or inhibitory activities.  Others have examined translational 
suppression by cotransfecting vectors containing cloned 3’UTR regions and miRNA in 
HEK293 cells (Jiao et al., 2010) and HTR-8/SVneo cells (Mouillet et al., 2010).  
Transfection with a 3’UTR reporter without addition of miRNA more closely recapitulates 
in vivo conditions by relying upon endogenous miRNA and translational machinery.  
Although there was no differential effect due to O2 concentration, flanking regions of the 
3’UTR (844-1363 and 2137-2315) strongly upregulated luciferase reporter, suggesting 
that these domains could have a role in stimulating HBEGF translation at 2% O2.  In 
contrast, regions towards the center of the 3’UTR (1363-1603 and 1778-2315), when 
present with the flanking regions, repressed luciferase production and are likely 
responsible for the overall repressive effect of the complete 3’UTR sequence.  Although 
a differential effect on reporter activity by oxygen was not observed, it could be 
hypothesized that when central and flanking regions of the 3’UTR are both present, the 
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suppressive influence could be attenuated by portions of the HBEGF mRNA not 
included in these reporter constructs, (e.g., the 5’UTR), resulting in accelerated 
translation of HBEGF at 2% O2.  For example, the 5’ terminal oligopyrimidine tract 
(5’TOP) motif in the 5’UTR of ribosomal proteins in neural U87 cells mediates 
translational upregulation (Orom et al., 2008).  Also, the 5’ noncoding region (5’NCR) of 
the hepatitis C viral genome (HCV) positively regulates accumulation of RNA (Jopling et 
al., 2005).  Therefore, miRNA or other regulatory factors that bind regions outside the 
3’UTR could interact with regions in the 3’UTR to induce translation at 2% O2. 
Translational regulation is often effected through miRNAs that interact with the 
3’UTR and induce formation of a protein complex (miRNA ribonucleoprotein; 
miRNP/RISC) that suppresses translation (Kim and Nam, 2006; Pillai et al., 2007).  
Therefore, we examined the role of miRNA in regulating HBEGF expression.  When 
miRNA production was blocked by adding siRNA to knock down DGCR8, HBEGF 
protein declined, suggesting that miRNAs are required to positively regulate HBEGF 
translation.  Hence, miRNA may either directly facilitate the upregulatory activity of the 
flanking regions of the 3’UTR (844-1363 and 2137-2315) or repress interactions of the 
interfering central domains with the flanking regions.  Functional miRNA seed 
sequences are predominantly located near stop codons or near the Poly-A tail in 
3’UTRs longer than 1.3 kb (Grimson et al., 2007) and translation can be increased due 
to potential miRNA-mediated action (Vasudevan and Steitz, 2007; Vasudevan et al., 
2007), suggesting that flanking regions of the HBEGF 3’UTR are more likely to be target 
by a miRNA-mediated mechanism.  Quantification of miRNAs that target HBEGF 
provided no evidence of their differential expression at 20% and 2% O2.  Though 
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miRNA may be required for upregulating HBEGF translation, they may be expressed 
constitutively in CTB cells.  These findings direct attention to proteins within the RNP 
complex that utilize HBEGF-targeting miRNA and may themselves be regulated by O2.  
Previous studies examining signaling downstream of HBEGF responsible for its 
autocrine upregulation (Jessmon et al., 2010) would suggest that the RNP proteins 
could be regulated downstream of MAPK signaling, either through phosphorylation or 
new transcription.  
The suppressive influence of the central region, which may act independently of 
miRNA, could be mediated through interacting proteins.  Regulatory proteins could be 
responsible for suppression of translation by interacting with the central regions of the 
3’UTR.  It has been demonstrated that RNA-binding proteins that bind the 3’UTR, 
including ARE-binding proteins, preferentially bind single-stranded RNA that can be 
provided by loops in the transcript (Hiller et al., 2006; Hudson et al., 2004). The protein 
Rnc1, a KH-type RNA-binding protein, binds UCAU tetranucleotide repeats in the 3’UTR 
of Pmp1 mRNA and stabilizes the transcript (Sugiura et al., 2003).  Pumilio/FBF (PUF) 
proteins are known to mediate translational repression of target RNAs by binding a 
recognized motif in their 3’UTRs (Chritton and Wickens, 2010).  Analysis of the 
secondary structure of the HBEGF 3’UTR indicates that there are more hairpins and 
loops in the flanking regions of the 3’UTR (clustered around nt 1100 and 2150, 
respectively) and in the central region (nt ~1300-2000).  Proteins could bind AREs in the 
central region to mediate the repression observed at 20% O2.  An examination of 
possible AREs in HBEGF using AREsite (Gruber et al., 2011) revealed that several 
different types of AREs potentially exist between 1503 and 1539, which is within one of 
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the downregulating regions of the 3’UTR.  Since more AREs are present in regions of 
the 3’UTR that were repressive, proteins that bind to these sequences could be 
responsible for the repression at 20% O2.  Site-directed mutagenesis would prevent 
binding of these proteins and could clarity the role of ARE-binding proteins in the 
regulation of HBEGF translation. 
Specific genes are translationally regulated by O2.  For example, low O2 
increases ATF4 protein, but doesn’t affect its mRNA (Lu et al., 2004; Vattem and Wek, 
2004).  In addition, treatment with thapsigargin to induce ER stress shifts ATF4 mRNA 
from monoribosomes to polyribosomes, indicating that its preexistent mRNA pool is 
inefficiently translated until cells experience ER stress.  This stress destabilizes 
eukaryotic initiation factor 2a (eIF2a), causing it to skip over the upstream open reading 
frame 2 (uORF2) in a process referred to as leaky scanning (Harding et al., 2000).  In 
addition, eIF2-GTP is expressed in limited amounts at low O2, which increases the time 
required for initiation complexes to reinitiate translation after skipping over uORF2.  This 
increased time allows the initiation complex to find the start codon, thus leading to 
preferential translation in hypoxia (Vattem and Wek, 2004).  Prediction software 
(EMBOSS GETORF) recognizes nine potential uORFs in the HBEGF 5’UTR.  UORFs 
are generally from 3-35 codons long and can mediate translational suppression or 
activation (Vilela and McCarthy, 2003).  Thus, it is possible that uORFs in the 5’UTR of 
HBEGF contribute to preferential translation at 2% O2, perhaps overriding the 
suppressive central region of the 3’UTR. 
The present study demonstrates that HBEGF is post-transcriptionally regulated 
by O2 and suggests that regions of its 3’UTR direct translationally suppressing and 
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activating mechanisms.  Evidence exists for a model in which flanking regions of the 
3’UTR mediate translational upregulation of HBEGF that is suppressed by factors 
recruited to the central region of the 3’UTR at 20% O2.  When O2 levels are reduced 
(2%), other portions of the HBEGF mRNA, such as factors present at the 5’UTR, 
interfere with elements at the central region of the 3’UTR, allowing miRNAs already 
bound to the flanking regions to direct protein synthesis.  While protein factors 
responsible for these mechanisms have yet to be identified, prior work suggests that the 
proteins are regulated downstream of HBEGF/ERBB and MAPK signaling (Jessmon et 
al., 2010).  This study provides a basic understanding of the complex mechanisms that 
regulate HBEGF expression in CTBs during environmental changes in early pregnancy 
(Armant et al., 2006; Jessmon et al., 2010; Jessmon et al., 2009).  Importantly, these 
mechanisms can rapidly up- or downregulate protein expression in response to changes 
in oxygen concentration without expending energy for de novo HBEGF transcription. 
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CHAPTER 6.  Conclusion 
  HBEGF is an important growth factor present during embryo implantation that 
regulates CTB physiology.  Its protein levels are greatly increased in the low O2 
environment found in early implantation through an autocrine, post-transcriptional 
mechanism (Armant et al., 2006).  Stabilizing HIF proteins at 20% O2 with CoCl2 
suggested that a transcriptional event occurs downstream of these O2-sensitive factors 
that leads to HBEGF upregulation.  Indeed, blocking nascent transcription at 2% O2 with 
α-amanitin confirmed that transcription is required.  Furthermore, microarray analysis 
identified that MMP2 and MMP15 are highly upregulated at 2% O2, suggesting that they 
may be the targets of this low O2-induced transcriptional event.  Prior studies 
established that matrix metalloproteinase (MMP) activity is necessary to induce 
autocrine HBEGF signaling that leads to an increase in its own translation (Armant et 
al., 2006).  Blocking the activity of MMP2, but not MMP9, abrogated the increase in 
HBEGF at 2% O2, which led to the hypothesis that low O2 induces transcription of 
MMP2, which is a regulated component of a proteolytic cascade responsible for 
proHBEGF cleavage from the cell surface and initiation of its signaling.  Preventing 
HBEGF signaling at 2% O2 with a specific antagonist of HBEGF or an inhibitor of its 
cognate receptors demonstrated that HBEGF then signals in an autocrine fashion to 
upregulate its own protein levels (Armant et al., 2006).  Inhibitors of the downstream 
signaling pathways ERK, MAPK14 (p38), and JNK, when added together, were also 
able to block its increase, indicating that HBEGF utilizes any of these three pathways to 
induce its autocrine-induced translation.  An examination of its protein and mRNA 
stability demonstrated that HBEGF protein is stable at 2% O2 and its transcripts exist in 
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equivalent amounts at both high and low O2.  Hence, its upregulation at low O2 occurs 
through a specific translational activation event. 
A post-transcriptional increase in HBEGF could be modulated by untranslated 
regions (UTRs) of its mRNA.  An examination of the 3’UTR of HBEGF for potential 
regulatory elements demonstrated that distinct regions, when inserted into a luciferase 
reporter vector, modulate either up- or down-regulation of luciferase translation.  
Specifically, flanking regions of the 3’UTR mediated translational upregulation, and 
central regions mediated translational downregulation.  The flanking regions are likely 
responsible for the increase in HBEGF translation at 2% O2.  This regulation could be 
due to RNA-binding proteins or miRNA that binds to the 3’UTR.  Knockdown of the 
miRNA-processing protein, DGCR8, decreased HBEGF protein levels, suggesting that 
miRNAs bind to the flanking regions of the 3’UTR and are responsible for the translation 
of HBEGF at 2% O2. 
Once upregulated at 2% O2, HBEGF signaling blocks apoptosis in CTBs induced 
by low O2 through the MAPK14 pathway (Jessmon et al., 2009).  This same pathway is 
utilized by HBEGF to block apoptosis when cells cultured at 2% O2 are reoxygenated.  
CTBs are likely exposed to reoxygenation in vivo during the 10th week of pregnancy 
when maternal arteries occluded by invading CTBs open and oxygen levels increase in 
the intervillous space of the placenta.  Hence, HBEGF upregulation prior to 10 weeks is 
essential to CTB survival both at low O2 and during subsequent reoxygenation. 
After the first 10 weeks of development, HBEGF accumulated by CTBs and in 
uterine tissue could induce CTB differentiation to a highly motile phenotype.  Inhibition 
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of signaling pathways downstream of the ERBB receptors demonstrated that HBEGF 
utilizes the ERK, JNK, MAPK14, and PI3K pathways to stimulate CTB motility.  HBEGF 
induces upregulation of ITGA1 and downregulation of ITGA6 protein (integrin-switching) 
in CTB cells through these four pathways.  This suggests that HBEGF could be 
responsible for inducing integrin expression patterns known to be characteristic of 
invading CTBs (Damsky et al., 1994; Zhou et al., 1997b).  Interestingly, the switch of 
integrin expression induced by HBEGF occurs without an accompanying change in 
mRNA, suggesting that a mechanism exists to rapidly upregulate integrin proteins and 
conserve energy spent on nascent transcription.  In the developmental program for 
implantation and placentation, such a mechanism would allow CTBs to quickly 
differentiate in response to changes encountered in growth factors, extracellular matrix 
or other extrinsic cues.   
 The syndrome preeclampsia, which is characterized by shallow CTB invasion 
into the maternal decidua and increased CTB apoptosis (Redman and Sargent, 2000), 
is associated with a dramatic reduction in placental HBEGF (Leach et al., 2002a).  This 
correlation suggests that reduced HBEGF signaling during placentation contributes to 
reduced conversion of the spiral arteries in preeclamptic pregnancies.  Although it 
remains to be discovered exactly how HBEGF is translationally regulated, the role of its 
3’UTR and miRNAs has been established and will likely be an important foundation in 
future studies of preeclampsia and the regulation of early pregnancy.  Future studies 
examining the mechanisms by which HBEGF regulates integrin-switching and 
cytoprotective mechanisms will likewise provide insights into trophoblast physiology 
during implantation.	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 HBEGF is a multifunctional protein in early pregnancy that induces 
cytotrophoblast (CTB) cell differentiation to an invasive phenotype, protects against 
apoptosis, and is involved in an autocrine signaling mechanism that leads to its own 
protein synthesis.  CTBs exist in a low O2 environment during the first 10 weeks of 
implantation, during which they invade the decidualized uterine stroma.  Inhibitors of 
intracellular signaling pathways demonstrated that at 20% O2 HBEGF induces an 
increase in cell migration through the ERK, MAPK14, JNK, or PIK3 pathways 
downstream of signaling through its ERBB receptors.  Also downstream of these four 
pathways, HBEGF induces a post-transcriptional increase in ITGA1 and decrease in 
ITGA6 expression (i.e., integrin-switching).  This phenotype is characteristic of invasive 
CTBs and is also induced by culture on Matrigel, but not on growth factor-reduced 
Matrigel.  TUNEL assays indicate that HBEGF signals through the MAPK14 pathway to 
inhibit apoptosis in CTBs induced by 2% O2 or reoxygenation injury.  Previous studies 
	   185 
have identified that HBEGF is specifically translated in CTBs at low O2 (2%), as 
compared to 20% O2.  Utilizing a chemical mimic of low oxygen (CoCl2) that stabilizes 
HIFα at 20% O2 and an inhibitor of nascent transcription, HBEGF protein was found to 
be upregulated downstream of HIF-mediated transcription of metalloproteinases.  In 
addition, a cascade involving MMP2 exists that leads to HBEGF shedding and its 
autocrine signaling at 2% O2.  It also signals through ERBB receptors to induce an 
autocrine post-transcriptional increase in its own protein levels through the ERK, 
MAPK14 or JNK pathways.  HBEGF mRNA is stable at both 20% and 2% O2 and its 
protein appears to be specifically regulated by O2.  Dual luciferase vectors containing 
various fragments of the HBEGF 3’UTR identified regions that may post-transcriptionally 
regulate HBEGF mRNA.  Regions flanking the 3’UTR may be bound by miRNA at 2% 
O2, leading to increased protein synthesis.  At 20% O2, sequences in the central portion 
of the 3’UTR mediate translational suppression and may override the influence of the 
flanking regions, leading to translational suppression of HBEGF at high oxygen 
concentrations.  These studies identify several mechanisms of HBEGF action in CTBs 
during early pregnancy.  In addition, they begin to address the rapid post-transcriptional 
regulation of HBEGF by O2, a phenomena that is important in the survival and 
successful implantation of CTBs during implantation.  
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